Abstract
The CNS critically relies on the formation and proper function of its vasculature during development, adult homeostasis and disease. Angiogenesis — the formation of new blood vessels — is highly active during brain development, enters almost complete quiescence in the healthy adult brain and is reactivated in vascular-dependent brain pathologies such as brain vascular malformations and brain tumours. Despite major advances in the understanding of the cellular and molecular mechanisms driving angiogenesis in peripheral tissues, developmental signalling pathways orchestrating angiogenic processes in the healthy and the diseased CNS remain incompletely understood. Molecular signalling pathways of the ‘neurovascular link’ defining common mechanisms of nerve and vessel wiring have emerged as crucial regulators of peripheral vascular growth, but their relevance for angiogenesis in brain development and disease remains largely unexplored. Here we review the current knowledge of general and CNS-specific mechanisms of angiogenesis during brain development and in brain vascular malformations and brain tumours, including how key molecular signalling pathways are reactivated in vascular-dependent diseases. We also discuss how these topics can be studied in the single-cell multi-omics era.
Similar content being viewed by others
Introduction
The human brain constitutes only 2% of body mass but receives 20% of cardiac output and consumes 20% of the body’s total oxygen and glucose, underlining the crucial importance of the CNS vasculature for a properly functioning brain1,2. Accordingly, the human brain vasculature is composed of an extensive and complex network of blood vessels, with a total length of 400 miles and including up to 100 billion capillaries2. The brain vascular network is established during embryonic and postnatal development via vasculogenesis (de novo formation of blood vessels) and sprouting angiogenesis (formation of new blood vessels from pre-existing ones), driven by various pro-angiogenic and anti-angiogenic factors3.
The endothelium of the brain vasculature displays specific properties that distinguish blood vessels in the CNS from those outside the CNS4. The most characteristic feature of the brain endothelium is the presence of a functional blood–brain barrier (BBB) — the highly selective semipermeable border between the vascular lumen of capillaries and the CNS parenchyma — established during embryonic and postnatal development by extrinsic cues provided by the perivascular microenvironment3,5 and intrinsic endothelial cell (EC) regulation mediated by homeobox transcription factors6. Blood vessels in the brain are embedded in an anatomical or structural unit termed the ‘perivascular niche’ (PVN), which describes a microenvironment that, in addition to ECs, includes perivascular cells (PVCs), such as astrocytes, pericytes, perivascular fibroblasts, neurons, stem cells, microglia and vascular smooth muscle cells (vSMCs)3,7,8,9. Together, ECs and PVCs in the PVN form the neurovascular unit (NVU)9,10,11, which is the functional correlate of the structural PVN9,10,11. Cellular and molecular interactions between ECs and PVCs in the NVU contribute to regulation of CNS angiogenesis9,10,11.
Developmental vascular growth in the CNS involves general angiogenic mechanisms (that is, mechanisms involved in angiogenesis inside and outside the CNS9) and CNS-specific angiogenic mechanisms. The NVU becomes deregulated in vascular-dependent brain pathologies such as brain tumours and brain vascular malformations, in which angiogenic signalling pathways become activated and lead to the formation of leaky, tortuous and dysfunctional neovessels via various modes of neovascularization9,12,13. These angiogenic pathways are, at least in part, reactivated signalling cascades regulating vascularization and the NVU and PVN during brain development9,12,13, but how these molecular mechanisms are involved in the initiation and progression of vascular-dependent brain pathologies remains poorly understood.
In this Review, we provide an overview of our current understanding of neovascularization in the developing, healthy adult and pathological brain (Fig. 1). Moreover, we describe recent insights into the human brain vasculature at the single-cell level, emphasizing the expanding knowledge of cerebrovascular cell type heterogeneity and the reactivation of developmental angiogenic signalling pathways in ECs of vascular-dependent brain pathologies. We review recent evidence regarding reactivated developmental signalling pathways in disease, focusing on molecules involved in angiogenesis and the neurovascular link (NVL), defined as the shared molecular mechanisms regulating both the vascular system and the nervous system9,14,15,16,17 (Fig. 2). We describe the involvement of these signalling cues in glial brain tumours and brain arteriovenous malformations (AVMs), two typical vascular-dependent CNS pathologies, with special focus on the distinction between CNS-specific cues and general molecular cues. Finally, we discuss several outstanding questions and emphasize how novel technologies used in the field of single-cell multi-omics may influence our understanding of brain vascular biology.
Modes of neovascularization
The neovascularization of organs and tissues can occur via different mechanisms (Fig. 1). During physiological development, such vascularization may involve the formation of new blood vessels from pre-existing ones, defined as sprouting angiogenesis (by far the best-described mode)9,12,15,18 (Fig. 1a), the de novo generation of blood vessels from mesodermal angioblasts or haemangioblasts (which differentiate into endothelial progenitor cells (EPCs) and subsequently into ECs) in a process called ‘vasculogenesis’19 (Fig. 1b), and/or the splitting of existing blood vessels, named ‘intussusception’12 (Fig. 1c). Three additional pathological modes of neovascularization may occur in glial brain tumours and in tissues undergoing regenerative processes (for example, following ischaemic stroke): vascular co-option, in which tumour cells co-opt blood vessels to grow along pre-existing healthy blood vessels (Fig. 1d), glioma (or glioblastoma) stem cell (GSC)-to-EC transdifferentiation or GSC-to-pericyte transdifferentiation20,21,22 (Fig. 1e) and vasculogenic (or vascular) mimicry, in which tumour cells integrate into the blood vessel wall, mimicking ECs12 (Fig. 1f). Whereas sprouting angiogenesis and vasculogenesis are primary contributors to neovascularization during brain development and in brain AVMs (Fig. 1g,i), all six modes of vessel formation have been described in brain tumours23,24,25,26 (Fig. 1h), as discussed later herein.
Sprouting angiogenesis
On a cellular level, sprouting vessels are guided by specialized ECs that extend multiple filopodia, the endothelial tip cells (ETCs)9,12,18. Behind the leading ETC, proliferating endothelial stalk cells are responsible for the elongation of blood vessels and the formation of a functional lumen3,9,12,15,18 (Fig. 1a). Subsequently, sprouting vessels anastomose and establish a three-dimensional, perfused and fully functional vascular network9,18 (Fig. 1a,g). Quiescent endothelial phalanx cells line the newly formed lumenized vessels and can be reactivated by pro-angiogenic stimuli3,12,18. Sprouting angiogenesis and ETCs, stalk cells and phalanx cells are regulated by pro-angiogenic and anti-angiogenic molecules, the balance between them being thought to determine the angiogenic response3,12,18,27 (Supplementary Table 1). Findings of recent studies have complemented this traditional view on sprouting and ETCs by suggesting a key role of venous ECs as the primary subtype of ECs — which proliferate and migrate against the flow to acquire the ETC position — that are responsible for sprouting angiogenesis and expanding vascular networks28.
On a molecular level, the VEGF–VEGFR–DLL4–Jagged–Notch signalling cascade is a key regulator of sprouting angiogenesis in both CNS tissues and non-CNS tissues and is thought to be the central pattern generator underlying ETC, stalk cell and phalanx cell differentiation3,9,29,30 in development and disease. The most important Notch ligands — DLL4 and Jagged 1 — have opposing roles in vessel formation, with DLL4 being anti-angiogenic and Jagged 1 being pro-angiogenic31. Interestingly, ETC and stalk cell specification is dynamically regulated by a feedback loop between the VEGF–VEGFR pathway and the DLL4–Jagged 1–Notch pathway32. Competition for the tip cell position occurs when activated ECs — expressing VEGFR1, VEGFR2, VEGFR3 and neuropilin 1 (NRP1) — upregulate DLL4 on their membrane, giving these ECs an advantage for the tip cell position29,32,33. DLL4 on ETCs activates Notch signalling in adjacent stalk cells, thereby downregulating VEGFR2, VEGFR3 and NRP1, upregulating VEGFR1 and restricting the ability of stalk cells to acquire the tip cell position30,34 and limiting tip cell numbers35. In contrast to DLL4, Jagged–Notch signalling drives tip cell selection and sprouting angiogenesis by antagonizing DLL4–Notch signalling31. MPDZ and the transcription factor ERG are key regulators of endothelial Notch–DLL4–Jagged 1 signalling36, underlining the dynamic nature of EC specification into ETCs, stalk cells and phalanx cells.
We previously described the regulatory effects of NVL molecules on peripheral and CNS angiogenesis during development, including their modes of action as either general cues or CNS-specific cues for vascular growth and their emerging molecular interactions with the VEGF–VEGFR–DLL4–Jagged–Notch pathway, and we do not comprehensively revisit this topic here9.
Vasculogenesis and intussusception
During embryonic development, vasculogenesis gives rise to the heart and the primitive vascular plexus. The vascular system is generated from precursor cells (angioblasts or haemangioblasts), and its establishment occurs in parallel with haematopoiesis (the formation of blood cells)37 (Fig. 1b). Angioblasts and blood cells constitute blood islets, which then fuse and give rise to a honeycomb-shaped primitive vascular plexus before the onset of heartbeats37. Once blood circulation has been established, primary vascular plexuses are remodelled into hierarchical networks with arteriovenous distinction37 (Fig. 1g). Subsequently, PVCs, including vSMCs (in the case of arteries and veins) and pericytes (in the case of capillaries), are recruited and stabilize the vascular network37,38. Molecularly, fibroblast growth factors (FGFs) induce the formation of angioblasts, whereas VEGFA plays key roles in the differentiation and chemotaxis of angioblasts and EPCs37.
Intussusceptive angiogenesis is defined as the invagination of the capillary wall into the lumen to split a single vessel in two39,40 (Fig. 1c). This mode of neovascularization was first observed during the development of peripheral organs41,42,43,44 and was subsequently characterized in CNS tissue45,46 and in several cancers, including glioblastoma47. Transcapillary intraluminal tissue pillars arise by invagination of the capillary wall into the vessel lumen in four consecutive steps40. First, a contact zone is established between two opposing capillary walls40. Second, reorganization of EC junctions and perforation of the vessel bilayer allows growth factors and cells to penetrate the lumen40. Third, an interstitial pillar core forms between the two new vessels at the contact zone and is filled with pericytes and myofibroblasts40. Finally, the pillars increase in diameter40 (Fig. 1c). Interestingly, intussusceptive angiogenesis allows reorganization of existing cells without the need for an increase in EC number, which is especially important during distinct stages of embryonic development in which the growth rate surpasses the cellular resources40. The molecular basis of vascular intussusception remains unknown.
ECs and PVCs in the NVU and BBB
Newly formed sprouting vessels are initially fragile and become stabilized by the recruitment of PVCs (such as pericytes, vSMCs and astrocytes)9,12, which is important for the establishment of functional, perfused blood vessels integrated into a three-dimensional vascular network3,9,48,49 (Fig. 3). Accordingly, ECs invading the CNS closely interact with PVCs of the surrounding parenchyma, thereby forming a functional NVU9,15,50,51 (Fig. 3a–d). As initially postulated in 1981, the CNS parenchyma provides instructive signals regulating EC sprouting into the CNS and induction of CNS-specific properties in ECs5,52. These structural and functional EC–PVC interactions result in the specific properties of CNS blood vessels, most importantly the establishment of the BBB53 (Fig. 3c,d), which is already established during embryonic development54,55 in a process regulated by extrinsic cues provided by the local CNS microenvironment5,9,52,56,57,58. Tight junction-specific proteins, such as CLDN5 and OCLN, are present at the BBB interface directly after blood vessels invade the brain at the embryonic stage and achieve functionality to meet barrier functions (which go beyond the presence or absence of passive permeability) according to the particular stage of brain development during the early postnatal period54,57,58,59,60. This highly regulated physical permeability barrier can become leaky in CNS pathologies such as brain tumours, brain vascular malformations, ischaemic stroke and some neurodevelopmental and neurodegenerative disorders4,60,61,62,63 (Fig. 4).
NVL molecules
Both the vascular system and the nervous system require coordinated guidance of their cellular and subcellular elements9,15,61. At the cellular level, axonal growth cones and ETCs exhibit similar lamellipodia and filopodia9,12,16,18,64 (Fig. 2a–c). At the subcellular level, axonal growth cones consist of a central domain containing microtubules and a peripheral domain composed of an actin meshwork (in lamellipodia) and F-actin bundles (in filopodia)9. Fan-like filopodial protrusions sense stimulatory and inhibitory guidance signals in the microenvironment and steer both the growing axon65,66 and the developing, newly forming blood vessels12,16,18,64,67 (Fig. 2a,b). F-actin structures have been found in ETC filopodia68, but the cytoskeletal organization of tip cells is less well described than that of axonal growth cones, mainly owing to technical limitations and the lack of specific ETC markers. Suggested tip cell markers — such as ESM1, APLN, RAMP3 and CLDN5 — that have emerged from microarray analysis and single-cell RNA sequencing (scRNA-seq) studies69,70,71,72,73,74,75,76 await full validation.
At the molecular level, numerous cues have been discovered that guide both ETCs and axonal growth cones9,12,15,16 (Fig. 2g,h). These cues include the four canonical axon guidance molecule families — netrins, semaphorins, ephrins and Slit proteins9,12,14,15,16,77 — and other axon guidance molecules, such as WNT proteins, SHH, bone morphogenetic protein (BMP), Nogo-A and Nogo-B, exert similar repulsive and attractive effects on neuronal growth cones78 and ETCs9,14,15,79,80 (Supplementary Table 2). In addition to these neural cues guiding blood vessels, classic angiogenic factors such as VEGFA and FGF2 and their receptors, endothelin 3, artemin and the receptor complex RET–GFRα3 can direct neuronal development and axonal growth during brain development9,14,15,79 (Fig. 2g). The NVL relies on direct cellular interactions between vascular cells and neural cells. For instance, sensory neurons and Schwann cells in the peripheral nervous system provide a template for the patterning of arteries but not veins during skin development, whereas neuronal release of VEGF induces arterial differentiation81. In the CNS, retinal ganglion cells and astrocytes provide a physical template for sprouting ECs while releasing pro-angiogenic and anti-angiogenic factors such as VEGFA, semaphorins and Nogo-A. Conversely, vessel-derived cues such as artemin and endothelin 3 guide growing axons in the retina82,83. Accordingly, ablation of radial glia84, oligodendrocyte precursor cells85 or astroglia86 results in a severe reduction in developmental angiogenesis14. Many of the NVL molecules interact with key downstream angiogenic signalling axes, most notably the VEGF–DLL4–Jagged 1–Notch and YAP–TAZ pathways9.
Angiogenesis and brain development
Embryonic CNS angiogenesis
Cellular mechanisms during embryonic brain development
During brain development in mice at embryonic day 8.5 (E8.5), a perineural vascular plexus (PNVP) (non-CNS tissue of mesodermal origin) forms around the neuroectodermal-derived neural tube via vasculogenesis (Fig. 3a–d and Supplementary Table 1), in which VEGFA derived from the neural tube interacts with VEGFR2 expressed on PNVP angioblasts9,50. This PNVP will later be transformed into arteries and veins of the pia and the arachnoid mater (leptomeninges) ensheathing the CNS tissue87. At E9.5, vessel sprouts from the PNVP invade the CNS parenchyma and form the intraneural vascular plexus (INVP) via sprouting angiogenesis9,54,64,88 (Fig. 3a,b). These perforating vessels of the INVP follow a radial course towards the ventricles. Once they are inside the ventricular zone, they branch in a circumferential fashion parallel to the ependyma, giving rise to a periventricular vascular plexus89 (Fig. 3a,b). Only after this lateral branching at the periventricular level do lateral branches from the INVP sprout at several levels throughout the cortical layers89.
In humans, the pial capillary anastomotic plexus is considered the functional and structural analogue of the PNVP in embryonic mice90. The pial capillary anastomotic plexus is a meningeal layer of extracerebral or non-CNS origin and is the source of all perforating vessels entering the cerebral cortex during later embryonic and postnatal stages67,90. The pial capillary anastomotic plexus is already detectable in 6-week-old human embryos and is separated from the underlying cortical tissue by the brain’s external glial limiting membrane90. Subsequently, pial capillaries perforate the external glial limiting membrane and grow into the cerebral cortex (comparable to the formation of the INVP in mice) from the eighth week of gestation onwards90. Whereas the CNS is, after vasculogenic formation of the PNVP, predominantly vascularized by sprouting angiogenesis27, vascularization of non-CNS tissues mainly relies on vasculogenesis91,92, for reasons that remain elusive.
General molecular mechanisms during embryonic brain development
Various general developmental pathways are active in both the CNS tissue and peripheral tissue, including the following: VEGFA–VEGFR–DLL4–Jagged 1–Notch signalling for appropriate vessel sprouting, patterning and vascular remodelling34,50,93,94 (see earlier herein for a description of this signalling pathway); YAP and TAZ as essential co-transcriptional activators of the Hippo pathway in ECs95; angiopoietins and their receptors TIE1 and TIE2 as modulators of vessel stability96,97,98; the classic axon guidance ligand–receptor pairs SLIT2–ROBO4 (refs. 99,100,101), SEMA3E–plexin D1 (ref. 102), netrin 4–UNC5B103 and ephrin B2–EphB4 (ref. 104); and the non-classic axon guidance cues, namely integrin αVβ8-activated TGFβ signalling105, WNT78, BMP78 and SHH78,79 (Supplementary Table 2). Although many of these pathways are active and important in CNS angiogenesis, they were first discovered in peripheral tissues, acting through a general (non-CNS-specific) molecular mode of action.
YAP and TAZ are transcriptional co-activators regulating the Hippo pathway and have crucial roles in organogenesis and embryonic vascular brain development in a non-CNS-specific manner. The VEGF and YAP–TAZ signalling pathways converge: VEGF stimulates Rho family members, thereby altering cytoskeletal dynamics, contributing to the activation of YAP–TAZ signalling106. YAP and TAZ, in turn, upregulate the gene expression of Rho family members, providing actin cytoskeletal rearrangements needed for ETC migration and stalk cell proliferation during embryonic and postnatal vascular brain development95,106.
Angiopoietin 1 (ANG1) and ANG2 bind to the tyrosine kinases TIE1 and TIE2 and directly act on ECs by modulating cell–cell and cell–extracellular matrix (ECM) communication and promoting or inhibiting angiogenesis, which is of crucial importance before E13.5 (refs. 107,108). ANG1 and ANG2 often have complementary roles in the development of a healthy vasculature; they modulate vessel stability and can be either pro-angiogenic or anti-angiogenic depending on the context96,98,108.
Classic axon guidance cue signalling, such as SLIT-dependent activation of the EC-specific receptor ROBO4 inhibits endothelial hyperpermeability induced by pro-angiogenic factors and enhances vascular stability99. ROBO4-mediated SLIT2-dependent suppression of cellular permeability occurs through inhibition of the small GTPases ARF6 and RAC109. In vivo, inhibition of ARF6 resembles ROBO4 activation by reducing pathological angiogenesis and vessel leakage in retinal hyperpermeability models during vascular development inside and outside the CNS99,101,110. The effects of ROBO4 silencing on human brain microvascular EC proliferation, migration and tube formation remain controversial101,110.
SEMA3A is a secreted protein mediating anti-angiogenesis via the NRP1 and plexin A–plexin D1 receptor complex111. The exact role of SEMA3A during developmental CNS angiogenesis is unknown, given the absence of a vascular phenotype in Sema3a−/− embryos112 and in NRP1sema mice113, which express a mutated variant of NRP1 that lacks the SEMA-binding domain. At E10, SEMA3A is expressed in vascular ECs in the spinal cord and dorsal aorta111. Interestingly, at E12.5, SEMA3A expression is stronger on ETCs than on stalk cells during INVP sprouting into the brain parenchyma and retina, indicating that its expressed on actively sprouting endothelium71,114. In zebrafish, Sema3A–plexin D1 signalling negatively regulates angiogenesis through modulation of soluble Flt1 expression115, illustrating the role of Sema3A–plexin D1 during embryonic brain vascularization in a non-CNS-specific manner.
SEMA3E–plexin D1 signalling negatively regulates angiogenesis inside and outside the CNS via interaction with the VEGF–DLL4–Jagged–Notch pathway. Plexin D1 can be detected in mouse embryos as early as E9.5 (refs. 102,116) as well as postnatally (postnatal day 2 to postnatal day 6) in the mouse retina102,116, where plexin D1 is expressed in ETCs and stalk cells but is absent in mature vessels, indicating that it has a role during developmental sprouting angiogenesis117. SEMA3E–plexin D1 signalling leads to downstream activation of the small GTPase RhoJ, with subsequent VEGF-induced DLL4 expression in retinal ETCs in vivo118 and in human umbilical vein ECs in vitro, contributing to the ETC and stalk cell selection in both the CNS vasculature and the non-CNS vasculature117. Whether SEMA3A–plexin D1 signalling or SEMA3E–plexin D1 signalling regulates PNVP and INVP formation during embryonic human CNS development remains to be explored.
Netrin 1 and netrin 4 are anti-angiogenic factors that act through binding to UNC5B (in the case of netrin 1) or to neogenin with recruitment of UNC5B (in the case of netrin 4) in peripheral tissues and the CNS in a general (non-CNS-specific) manner119,120,121. Netrin 1 and netrin 4 and their receptors act as repulsive or attractive cues, partially via regulation of VEGF signalling119, starting during embryonic developmental angiogenesis inside and outside the CNS119,120.
Last, the Eph family of receptor tyrosine kinases interacts with membrane-bound ligands called ‘ephrins’122. Ephrin B2, being the sole transmembrane ligand for EphB4, is specifically expressed in arterial angioblasts starting at around E9 (ref. 123). EC and perivascular mesenchymal cell123 interactions lead to activation of the ephrin B2–EphB4 axis, providing attractive and repulsive guidance cues for EphB-expressing cells in angiogenesis as well as regulation of migratory and invasive cellular functions in a non-CNS-specific way122,123.
Non-classic axon guidance cues such as the five members of the αV integrin subfamily (αVβ1, αVβ3, αVβ5, αVβ6 and αVβ8) are expressed by many different cell types, notably by neurons and ECs of the brain (acting as NVL molecules) but also in other organs and tissues, and bind to RGD peptide motifs present on many shared ECM ligands, most importantly to latent TGFβ proteins124. The αV integrin is of particular interest in genetic studies in mice as it is an important regulator of embryonic cerebrovascular morphogenesis (although the actions of αV integrin are not exclusively CNS specific)125,126. Integrin αVβ8 activates ventral–dorsal TGFβ gradients in the brain, inhibiting EC sprouting and stabilizing blood vessels via downstream TGFβ1–TGFBR2–ALK5–SMAD3 signalling105,125,127,128. Ablation of αV integrin-coding or β8 integrin-coding genes in embryonic brain ECs causes pathological vascular phenotypes, including EC hyperproliferation and intracerebral haemorrhages105,127. In mice, knocking out either of the genes encoding the TGFβ signalling co-receptors — that is, ALK1 (encoded by Acvrl1, also known as Alk1) and endoglin (ENG; encoded by Eng) — causes embryonic lethality at E11.5 (refs. 129,130).
Several axon guidance molecules, including the WNT proteins, SHH and BMP, guide both axonal growth cones78 and ETCs according to the concept of the NVL79 (Fig. 2). The specific effects of NVL molecules on ETC guidance, with the exception of the CNS-specific WNT ligands WNT7A and WNT7B (which are discussed later), are less clear than their roles in axon guidance15.
CNS-specific molecular mechanisms during embryonic brain development
CNS-specific molecular cues that are active in developmental angiogenesis include WNT7A and WNT7B, GPR124 and its co-receptor RECK131,132,133,134,135,136,137 with suggested upstream involvement of netrin 1–UNC5B138,139, DR6 and TROY50,140, the norrin–FZD4–LRP5–TSPAN12 complex141,142,143 and the recently discovered brain EC-specific WNT regulator PPIL4 (ref. 144) (Supplementary Table 2). Even though absolute CNS specificity is nearly impossible to prove, most of the CNS-specific molecular mechanisms that regulate the vasculature were shown to be absent in a number of peripheral tissues.
Endothelial β-catenin signalling is crucial for the establishment and maintenance of a functional BBB during embryonic and postnatal brain development145,146. To activate the β-catenin pathway in a CNS-specific manner, the ligands WNT7A and WNT7B and/or norrin with its co-activator TSPAN12 (in retinal angiogenesis) is produced by glial cells or neurons to activate the co-receptors LRP5 and LRP6 on ECs146. Mutations in the genes encoding β-catenin, norrin, FZD4, LRP5, LRP6 and TSPAN12 can cause inherited defects in retinal vascularization, whereas targeted mutations in the genes encoding WNT7A and WNT7B cause defects in both retinal and brain angiogenesis143. The binding of WNT7A and WNT7B to two membrane proteins expressed on CNS ECs —GPR124 and RECK — specifically enhances intracellular β-catenin signalling and is crucial for proper vessel ingression into the CNS parenchyma and the formation of CNS-specific properties of the INVP131,133,134,135,136,147,148. Interestingly, in regions where the barrier function of the BBB is physiologically reduced to monitor serum osmolarity and electrolyte balance — most notably the microvasculature of the circumventricular organs, the choroid plexus and the choriocapillaris and ciliary bodies in the eye — EC WNT–β-catenin signalling is kept at low rates, resulting in strict maintenance of this high-permeability state149,150.
Recent studies showed that EC-specific deletion of the gene encoding the non-CNS-specific receptor UNC5B in mice induces loss of BBB integrity, characterized by reduced CLDN5 levels and increased expression of the permeability protein PLVAP138,139. UNC5B-bound netrin 1 interacts with the CNS-specific WNT7A and WNT7B co-receptor LRP6, leading to downstream activation of the WNT–β-catenin pathway inside but not outside the CNS (for example, there are no effects on the vasculature in the lungs, heart and kidneys). This signalling might be an important CNS-specific downstream mechanism regulating BBB integrity138.
Embryonically, mutations in Gpr124 (also known as Adgra2) or Reck severely impair CNS angiogenesis and barriergenesis133,136,148. Endothelial-specific Gpr124 deletion causes embryonic lethality in mice from E15.5 onwards owing to angiogenic defects in the forebrain and neural tube, whereas Gpr124 overexpression produces CNS-specific hyperproliferative vascular malformations135. This forebrain (but not midbrain or hindbrain) localization pattern suggests that GPR124 mediates EC migration towards regional guidance cues in the embryonic CNS135. Endothelial β-catenin signalling promotes sprouting angiogenesis, ETC formation and VEGFR expression during postnatal brain and retinal vascular development151. Increased β-catenin levels also lead to upregulation of DR6 and TROY, which are required for vascular and BBB development and maintenance in a CNS-specific manner in zebrafish and mice140. ppil4−/− zebrafish exhibited a brain EC-specific phenotype, including necrosis in the dorsal midbrain and embryonic lethality 2 days after fertilization144. Interestingly, PPIL4 exerts brain EC-specific modes of action via a downstream effect on WNT signalling cascades144. Finally, the formation of arteriovenous connections during CNS development is partially mediated by the receptor–ligand pair Cxcr4–Cxcl12b in the CNS but not in the trunk of zebrafish embryos, suggesting it has a CNS-specific nature152.
Postnatal CNS angiogenesis
Cellular angiogenic mechanisms during postnatal brain development
Sprouting angiogenesis continues postnatally and further remodels and expands the CNS vascular network3,9,153 (Fig. 3e,f). Whereas sprouting angiogenesis and ETCs advance in a radial manner during embryonic development88, postnatally, ETCs spread in all directions of the various cortical layers, mostly emanating from the main vessel branches established during brain embryogenesis3,153,154 (Fig. 3e,f).
General angiogenic molecular mechanisms during postnatal brain development
Much less is known about the molecular regulation of brain angiogenesis and vascular patterning postnatally than in the embryonic stage. Many molecules and molecular pathways are probably active during both developmental stages, including the VEGFA–VEGFR–DLL4–Jagged 1–Notch pathway, YAP–TAZ, integrin αVβ8, SEMA3A and SEMA3E, and ephrin B2–EphB4 (ref. 50) (Supplementary Table 2). We identified Nogo-A as a major negative regulator of sprouting angiogenesis, ETCs and vascular network formation in the postnatal brain17, whereas its role during embryonic vascular brain development remains unclear. The vascular receptor for the Nogo-A isoform Nogo-B, NgBR155, regulates both embryonic and postnatal brain angiogenesis9,156,157,158,159. NgBR knockdown in zebrafish models stopped Nogo-B-stimulated EC migration and reduced VEGF-induced phosphorylation of AKT and EC morphogenesis in a general (non-CNS-specific) manner9,156.
CNS-specific angiogenic molecular mechanisms during postnatal brain development
Similarly to observations made during the embryonic stage, postnatal deletion of Gpr124, Reck or Ndp (which encodes norrin) compromises angiogenesis and BBB integrity in a CNS-specific manner133,136. Whereas most of the CNS-specific mechanisms regulating vascular brain development at the embryonic stage also regulate postnatal brain angiogenesis and barriergenesis, little is known about the molecular mechanisms that regulate CNS vascular development solely at the postnatal stage (Supplementary Table 2).
Summary
In conclusion, during both embryonic and postnatal brain development, sprouting angiogenesis is highly active and vascular sprouts led by ETC filopodia invade the CNS tissue to establish a functional vascular network. Molecular pathways regulating developmental brain angiogenesis in a general or CNS-specific way are increasingly being discovered, but our knowledge of these molecular processes and their interactions with the VEGF–VEGFR–DLL4–Jagged–Notch pathway and the Hippo–YAP–TAZ pathway remains incomplete9,50 (Supplementary Table 2). In the adult human brain vasculature, most of the aforementioned developmental pathways are downregulated, keeping the vasculature in a quiescent homeostatic state9,61,160,161 (Fig. 3g–j).
Angiogenesis in brain tumours
In contrast to the healthy adult quiescent vasculature, brain tumours are characterized by aberrant angiogenesis and alterations to the BBB61,162, to CNS specificity and to arteriovenous specification of ECs24, but to what extent developmental signalling axes are reactivated in brain tumours remains poorly understood. Here we focus on intra-axial glial brain tumours, which are a classic example of highly angiogenic brain tumours characterized by the crucial role of their vasculature and aberrant capillary beds in disease initiation and progression163,164,165,166.
Glial brain tumours
Vascular proliferation is an important pathological hallmark of glioblastomas (high-grade gliomas), which have one of the most extensive vascular systems among all solid tumours and vascular proliferation is an important pathological hallmark164,165,166. However, targeting glioma vascularization using an anti-VEGF therapy167, a combined anti-FGF–anti-VEGF therapy168 or other approaches has resulted in disappointing results166,169,170,171, probably owing to an incomplete understanding of the cellular and molecular mechanisms regulating angiogenesis and the NVU and PVN in glial brain tumours.
Modes of neovascularization
In glial brain tumours, all six mechanisms of neovascularization have been characterized23,24,25,26,172 (Figs. 1, 4c,d and 5 and Supplementary Table 1).
Vascular co-option
Chronologically, the first mode of neovascularization in glial tumours is vascular co-option, involving the organization of tumour cells into perivascular cuffs around microvessels of the surrounding healthy brain tissue to form an early, initially well vascularized tumour mass25 (Figs. 1d and 4c,d and Supplementary Table 1). This process mostly occurs in highly vascularized tissues but may also occur in malignancies both inside and outside the CNS, including liver cancer173, lung tumours174, breast-to-brain metastases175 and glial brain tumours176, as well as in tumour recurrence and metastatic growth following administration of anti-angiogenic therapies in glioblastoma13,176 (Figs. 1d,h and 4c,d and Supplementary Table 1).
At the cellular level, cytoplasmic extensions of glioblastoma cells termed ‘flectopodia’ modify the normal contractile activity of pericytes surrounding pre-existing vessels, resulting in co-option of these blood vessels, thereby illustrating cellular interactions within the tumour NVU and PVN177. Molecularly, inhibition of the small GTPase CDC42, a principal regulator of cell polarity and actin cytoskeletal organization, impairs vessel co-option, thereby favouring an innate immune response against the tumour177. Co-opted vessels do not undergo sprouting angiogenesis as a direct next step but first regress via disruption of EC interactions and proteolysis of the basement membrane and ECM, mediated by expression of ANG2 (ref. 178) (Supplementary Table 1). ANG2 is expressed by ECs in co-opted vessels at an early stage and appears to counter the constitutive expression of ANG1 in healthy tissues. ANG2 is upregulated through HIF1α-dependent mechanisms and contributes to the formation of the leaky, tortuous and dysfunctional vessel characteristics of glioblastoma179. Other molecular players in vascular co-option include bradykinin, EGFRvIII180, MDGI181 and ephrin B2 (ref. 182). Ultimately, the remaining tumour is rescued by sprouting angiogenesis at the tumour borders25,39,182 (discussed later). To date, no CNS-specific mechanisms regulating vascular co-option in glial tumours have been identified.
Sprouting angiogenesis
Glioma-associated sprouting angiogenesis begins after ANG1-mediated and ANG2-mediated breakdown of existing, co-opted vessels. In the presence of ANG2, VEGF promotes EC migration and proliferation and stimulates sprouting of pre-existing blood vessels29. Under hypoxic conditions characterized by high HIF1α expression, VEGF ligands and receptors are upregulated and VEGFA binds VEGFR2 and VEGFR3, resulting in MAPK (ERK)-dependent upregulation of VEGF signalling in gliomas64. DLL4 inhibition leads to non-productive angiogenesis with aberrantly high ETC and filopodia numbers and suppression of tumour growth in glioma models, whereas prolonged complete inhibition of DLL4 resulted in highly vascular tumours with a haemangioblastoma phenotype, illustrating this carefully balanced mechanism183 (Figs. 1a,h, 4c,d and 5f,g and Supplementary Tables 1 and 2). Stabilization of the newly formed capillaries requires interactions between ECs, PVCs and ECM components184,185,186,187. For instance, during vessel lumen formation, pericytes are recruited towards the newly formed vessels in response to platelet-derived growth factor (PDGF) and matrix metalloproteinase upregulation in activated glioma ECs to stabilize the vascular sprout53,185,187,188.
Bone marrow-derived vasculogenesis
Vasculogenesis is important in tumour biology, and involves the differentiation of three types of circulating bone marrow-derived cells: most importantly, EPCs and pericyte progenitor cells25, and the less well characterized CD45+ vascular modulatory cells189 (Figs. 1b,h and 4c,d and Supplementary Table 1). Multiple studies showed that impaired recruitment of EPCs interferes with tumour progression in human gliomas190,191. EPCs, defined by the expression of progenitor markers (CD34 and CD133) and EC markers (CD31 and VEGFR2) regulate angiogenesis-mediated tumour progression indirectly via paracrine secretion of pro-angiogenic growth factors192 and by direct luminal incorporation into nascent sprouting vessels81,193.
In a transgenic mouse model of liver carcinogenesis, CCR2+ and CCR5+ EPCs were incorporated into the tumour vasculature191. Glioblastoma recruits CXCR4+ EPCs in the process of bone marrow-derived vasculogenesis through activity of HIF1α and its target SDF1α194. Bone marrow-derived vasculogenesis is important in glioblastoma resistance to initial chemoradiotherapy and pharmacological VEGF inhibition195, and clinical trials targeting inhibition of the SDF–CXCR4–CXCR7 axis combined with anti-VEGF therapy in glioblastoma are ongoing196. Clinically, the number of EPCs in peripheral blood of patients correlates with glioblastoma blood vessel density and angiogenic activity and might serve as a biomarker for the identification of patients who may benefit from anti-angiogenic therapy197. The contribution of pericyte progenitor cells to pathological glioblastoma angiogenesis is a matter of debate, given that the pericyte progenitor cell population varies dramatically depending on the stage of disease and that glioblastoma shows a relatively low pericyte coverage of 10–20% (with substantial interpatient variability), compared with 67% in mammary carcinomas and 65% in colon carcinomas198.
Molecularly, EPC migration and proliferation are regulated by VEGFA–VEGFR2–VEGFR3–MAPK signalling, with VEGFR2 and VEGFR3 being expressed on EPCs199, whereas EPC homing is regulated by key angiogenic chemokines (CXCL1, CXCL7, CXCL12 and CCL2), their respective receptors (CXCR2, CXCR4 and CCR2) and the TGFβ–SDF1α–CXCL12 axis200. CNS-specific molecular mechanisms involved in vasculogenesis remain to be discovered.
Intussusception
Intussusceptive angiogenesis has been characterized in several cancers39, including glioblastoma47. Nico et al. detected a number of connections of intraluminal tissue folds with the opposite vessel walls (corresponding to a key step in the process of intussusception (Fig. 1c)), thereby suggesting the existence of this mode of neovascularization in human glioblastoma47. The relevance of intussusception to human brain development and brain disease remains unknown, as do its underlying molecular mechanisms and whether it displays a CNS-specific or general mode of action.
Glioma stem cell to EC and glioma stem cell to pericyte transdifferentiation
Located in the glioblastoma PVN, GSCs are closely associated with microvascular ECs, and studies have proposed that soluble factors secreted by ECs — including VEGFA201, IL-8 (ref. 202), SHH203 and CD9 (ref. 204) — and adhesive connections between ECs and GSCs control the fate and survival of GSCs, thereby affecting the aggressiveness of glioblastoma (Figs. 1e,h and 4c,d and Supplementary Table 1). A subpopulation of glioblastoma-derived ECs harbours the same somatic mutations (for example, mutation in the gene encoding EGFRvIII and chromosome 7 amplification) as GSCs, indicating that a notable portion of the vascular endothelium has a neoplastic origin and GSCs can transdifferentiate into functional ECs, thereby contributing to tumour vascularization20,21,205. Recently, the P4HA1–COL6A1 axis was identified as a modulator of GSC-to-EC transdifferentiation206. Additional candidate modulators of this process include ETV2, a master regulator of EC development, and the transcription regulator TWIST1, and their expression positively correlates with malignancy grade207,208.
Mechanistically, treatment with the chemotherapeutic drug temozolomide increases the expression of GSC-specific markers in glioblastoma ECs and induces the transdifferentiation of GSCs to glioblastoma ECs, thus identifying chemotherapeutic stress as a driver of this mode of neovascularization209. Ionizing radiation has also been shown to initiate GSC-to-EC transdifferentiation through the previously described TIE2 pathway210,211. Interestingly, GSCs can also give rise to tumour pericytes supporting vessel function and tumourigenesis22. In vivo cell lineage tracing in a glioblastoma xenograft model demonstrated that GSCs generate the majority of glioblastoma pericytes (predominantly via TGFβ signalling) and revealed that selective cell arrest of GSC-derived pericytes led to vessel wall disruption in vivo22. Transdifferentiation of GSCs to pericytes along with stem cell plasticity and angiogenic properties of GSCs are regulated predominantly by the NOTCH1 pathway in hypoxic conditions212. The observation that GSC-derived pericytes bear tumour-specific genetic alterations distinguishing them molecularly from normal pericytes (for example, mutations in the gene encoding EGFRvIII, chromosome 7 amplification, or PTEN or chromosome 10 deletion) provides possibilities to specifically target these tumour-derived pericytes22.
Clinically, pericyte coverage of tumour vasculature inversely correlates with response to chemotherapy and survival in individuals with glioblastoma, suggesting that pericytes with a neoplastic origin in glioblastoma may regulate the brain tumour barrier, which impacts the efficiency of drug delivery213. Tumour vascular endothelium and GSC-derived pericytes have been suggested as novel targets for anti-angiogenic therapy165,166,214. Cancer stem cell to EC or pericyte transdifferentiation is a non-CNS-specific process that has been described in non-CNS tumours215.
Vasculogenic mimicry
‘Vasculogenic mimicry’ (VM) refers to the ability of tumour cells to form functional vessel-like networks216,217 (Figs. 1f,h and 4c,d). Tumour cells lining these erythrocyte-containing ‘vascular’ channels, which are devoid of ECs, continue to express tumour cell markers. First identified in melanomas216, this mode of neovascularization has been reported in various cancers inside and outside the CNS218,219,220 and in glial brain tumours221.
Molecularly, hypoxia promotes VM through expression of VE-cadherin (also known as CD144) on tumour ECs and tumour cells222. In glioblastoma, tumour cells lining the vasculature display an undifferentiated embryonic-like biological and molecular phenotype, suggesting the involvement of GSCs and reactivation of neurodevelopmental signalling programmes223. Several molecules and ligand–receptor pairs associated with anaplastic properties of these GSCs are associated with VM formation, including TGFβ, Nodal, EphE2 and VE-cadherin224. The incidence of VM was markedly higher in high-grade gliomas than in lower-grade gliomas225. Overall survival was notably lower and microvascular density was higher in people with VM-positive high-grade gliomas than in individuals with VM-negative high-grade gliomas, indicating a notable contribution of VM channels to glioma blood supply225. IGFBP2 (ref. 226), leptin receptor ObR227, the RNA-binding protein ZRANB2 (ref. 228) and several specific long non-coding RNAs229 and microRNAs230 stimulate VM, whereas histone deacetylase inhibitors impair the process of VM in human glioblastoma231. CNS-specific mechanisms of VM have not been discovered to date.
Developmental pathways in glial tumours
General molecular mechanisms reactivated in glial brain tumour angiogenesis
Typical examples of developmentally active general mechanisms that are reactivated in pathological glial brain tumorigenesis include VEGF–VEGFR, DLL4–Jagged–Notch, YAP–TAZ, PDGF–PDGFR, SLIT2–ROBO4, semaphorin–plexin, semaphorin–neuropilin, ANG2–TIE1, ANG2–TIE2 and ephrin B2–EphB4 signalling (Fig. 5f and Supplementary Table 2). An increase in VEGFA expression has been associated with an increase in glioma malignancy and poor prognosis232. A frequent hallmark of glioma-associated angiogenesis is the activation of the developmentally active RTK signalling pathways233, most commonly caused by amplifications of, mutations in or overexpression of EGFR in GSCs and ECs or pericytes234, contributing to sprouting angiogenesis and stem cell to EC transdifferentiation or stem cell to pericyte transdifferentiation233. Mutations in EGFR, in particular mutations encoding the EGFRvIII variant, lead to ligand-independent and constitutive activation of the EGFR signalling pathway235. This prolonged activation leads to tumour progression and stimulation of angiogenesis via secretion of proteases, which degrade the ECM and enable ECs to proliferate in the surrounding matrix via upregulation of unidentified pro-angiogenic molecules235.
The Notch pathway is linked to several glioblastoma-specific responses to hypoxia, angiogenesis and tumour growth183,236,237. Combined targeting of EGFR signalling and Notch signalling results in decreased cell viability and EC sprouting compared with use of either of the monotherapies, supporting an important role of Notch–EGFR signalling crosstalk in glioblastoma238. However, inhibition of both the EGFR signalling pathway and the Notch signalling pathway is not sufficient to fully stop EC sprouting in human glioblastoma cell cultures, despite almost complete inhibition of VEGF secretion upon combined treatment, suggesting that VEGF-independent pro-angiogenic factors contribute to sprouting angiogenesis238. Indeed, VEGF-independent YAP–TAZ upregulation was observed in glioblastoma on both glial tumour cells and tumour-associated ECs, and this correlated with malignancy grade95,239.
PDGFs, which have several critical roles in physiological embryonic development, are also known to have an important role in sprouting angiogenesis in human glial brain tumours240,241. Five different PDGF isoforms (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD) activate cellular responses through two different receptors (PDGFRα and PDGFRβ; the latter is mainly involved in tumour ECs)242. PDGF-mediated endothelial-to-mesenchymal transition induces EC resistance to anti-angiogenic therapies that target VEGF pathways by downregulating VEGFR2 expression in ECs that were isolated from human glioblastoma samples241.
Among the reactivated general molecular mechanisms regulating glial brain tumour vasculature, signalling by the classic axon guidance cue ephrin B2–EphB4 regulates ETC guidance in brain tumour angiogenesis, and ephrin B2–EphB4 expression is associated with accelerated glioma progression and a worse clinical prognosis in patients with glioblastoma123,243. Sawamiphak et al. found a reduction of tumour volume of up to 25% in an intracranial glioma model in ephrin B2-deficient mice104. Furthermore, ephrin B2 activation in ETC filopodia regulates VEGFR2 internalization, which is required for downstream signalling and VEGF-induced tip cell filopodial extension and sprouting angiogenesis104. Additionally, in a glioblastoma EphB4 overexpression model, reactivation of this developmentally active ephrin B2–EphB4 receptor–ligand pair in glial brain tumours and subsequent overexpression of EphB4 leads to a stabilization of pericyte–EC interactions, intact pericyte coverage and cellular proliferation, all hallmarks of anti-angiogenic therapy-resistant tumour vessels244.
Active during physiological embryonic and postnatal vascular development, TIE1-bound ANG2 and TIE2-bound ANG2 were also detected in tumour cells and ECs in high-grade gliomas (they are present at negligible levels in low-grade gliomas)245,246. Reactivation of TIE receptor signalling during ectopic overexpression of ANG2 in glioblastoma accelerates tumour progression and compromises the benefits of anti-VEGFR treatment in murine glioblastoma models247. Dual inhibition of ANG2 and VEGF receptors normalizes tumour vasculature and prolongs survival in glioblastoma models247.
SLIT2–ROBO4 signalling constitutes another classic axon guidance cue regulating vascular development99,248. ROBO4 is markedly downregulated in ECs cultured in glioma-conditioned medium, and binding of SLIT2 to ROBO4 suppresses glioma-induced EC proliferation, migration and tube formation in vitro by inhibiting VEGFR signalling249.
Among the five members of the αV integrin subfamily, αVβ8 — expressed in neurons, ECs and PVCs — is of particular interest as an important regulator of angiogenesis in the developing brain125,126. In mosaic mouse models of astrocytoma, xenografts and cell culture systems of human glioblastoma, αVβ8 integrin-activated TGFβ proteins suppress pathological angiogenesis and differentially regulate glioblastoma (vessel) growth via autocrine activation of TGFβ signalling pathways250.
Other classic axon guidance cues such as netrin 1 and semaphorins (for example, SEMA3D, SEMA3E, SEMA3F and SEMA4D) play important roles in glioblastoma tumorigenesis and progression by affecting infiltration patterns and the aggressiveness of GSCs251,252,253.
Recently, we identified nucleolin, a neurodevelopmental regulator of angiogenesis in the human fetal brain vasculature, as a reactivated, positive regulator of sprouting angiogenesis in glioblastoma254. In our own scRNA-seq dataset, we have identified various reactivated fetal signalling pathways in human low-grade and high-grade glioma or glioblastoma with a general (non-CNS-specific) mode of action, including, cell–ECM interaction-related and cell–cell interaction-related signalling pathways, as well as WNT, BRAF, Notch, VEGF–VEGFR1 and VEGF–VEGFR2, IL-8–CXCR1, PI3K–AKT, PDGF–PDGFR, Hedgehog, angiopoietin–TIE1, angiopoietin–TIE2, ephrin and integrin signalling cascades163.
CNS-specific molecular mechanisms reactivated in glial brain tumour angiogenesis
Only a few studies have been published to date relating to the CNS-specific regulation of angiogenesis in primary glial brain tumours12,132 (Fig. 5g and Supplementary Table 2). WNT7A/WNT7B–β-catenin signalling, regulating embryonic and postnatal developmental angiogenesis in a CNS-specific manner via the co-activator GPR124, also regulates pathological angiogenesis in mouse models of glioblastoma and ischaemic stroke132,145,146. Mice in which Gpr124 was conditionally knocked out in ECs (Gpr124-CKO mice) exhibited decreased vessel density and increased loss of CNS microvascular integrity, measured by BBB leakage, compared with heterozygous control animals in both the model of stroke255 and the model of glioblastoma132. To investigate whether GPR124 functions via downstream WNT–β-catenin signalling to regulate BBB function, primary cultured brain ECs from adult Gpr124-CKO mice and the Gpr124-heterozygous control group were transduced with Wnt7b-expressing adenovirus. Upregulation of WNT7B signalling resulted in increased BBB integrity in glioblastoma by positively regulating tight junction proteins, pericyte coverage and cell–ECM interactions in the ECs from adult global Gpr124-heterozygous mice but not in those from Gpr124-CKO mice132, indicating a crucial role for WNT7A/WNT7B–GPR124–RECK–FZD–LRP signalling in brain tumour BBB integrity and identifying this molecular signalling pathway as a possible therapeutic CNS-specific target in glioblastoma132,256. More recently, engineered WNT7A ligands were shown to enable BBB repair in mouse models of stroke and glioblastoma by selectively binding the WNT7A/WNT7B-specific GPR124–RECK co-receptor complex, thereby acting as BBB-specific WNT activators to induce WNT signalling257. It remains to be determined whether WNT–GPR124 signalling also affects pathological vascularization in non-CNS tumours or whether this signalling axis keeps its developmental CNS specificity in vascular-dependent CNS pathologies such as brain AVMs.
Other regulators of developmental brain angiogenesis such as norrin, DR6 and TROY have been reported to have effects in brain tumours such as medulloblastoma (mainly on neuronal migration, not on angiogenesis)258,259, but their potential regulatory roles in angiogenesis in glial brain tumours and other non-CNS tumours remain to be investigated. Similarly, in light of the recently identified CNS-specific UNC5B–netrin 1-mediated interaction with LRP6 (ref. 138), it would be interesting to see whether intravenous injection of netrin 1 could increase WNT–β-catenin signalling in the BBB and repair CNS endothelial barrier breakdown in glial brain tumours.
From the findings taken together, reactivation of the VEGF–VEGFR–DLL4–Jagged–Notch signalling axis, along with the YAP–TAZ pathway, is of crucial importance in the initiation and progression of angiogenesis in glial brain tumours. Many of the discussed classic axon guidance cues of the NVL are reactivated in glial brain tumours in a general way. Besides possible involvement of netrin 1 and semaphorins in glioblastoma vascularization252, the role of additional classic and non-classic axon guidance cues and CNS-specific cues in this process remains to be explored.
Molecular mechanisms in glial brain tumour vasculature at the single-cell level
scRNA-seq is a powerful approach to study brain tumour (including low-grade and high-grade glioma) biology260,261,262,263,264. Single-cell techniques enable the study of genetic heterogeneity265,266, developmental cellular lineages and hierarchies, and stem cell programmes261,262,264,267, as well as the investigation of the various cell types in the tumour microenvironment266. Until recently, however, single-cell sequencing had not been applied to the study of the glioma vasculature. Xie and colleagues used scRNA-seq to study freshly isolated ECs from human glioblastoma tissues, gaining molecular insight into the heterogeneity of the human BBB and the pathological neovascularization in glioblastoma265. They identified distinct EC clusters that represent different states of angiogenesis and EC activation and impairment of the BBB in both the tumour centre and the tumour periphery, thereby highlighting the importance of different regions within the tumour with regard to the tumour vasculature.
To address the molecular heterogeneity of brain ECs (and PVCs) across development and disease, we recently created the first large-scale single-cell molecular atlas of the developing fetal, healthy adult and diseased human brain vasculature, focusing on brain vascular malformations and brain tumours, including AVMs and low-grade and high-grade gliomas163. We performed scRNA-seq on approximately 600,000 freshly isolated ECs and PVCs from 47 fetuses and adult patients163. This unprecedented insight into EC and PVC heterogeneity and functional specialization of the human brain vasculature in development, health and disease at the single-cell level revealed alterations in arteriovenous differentiation and CNS-specific properties, upregulation of major histocompatibility complex class II molecules and a central role for ECs in the brain NVU in pathological ECs across different brain diseases, including brain tumours and brain vascular malformations. Notably, we observed a marked increase in the angiogenic capillary EC cluster in glioblastoma (and lung cancer brain metastases) and to a lesser extent in lower-grade gliomas as compared with the adult control brain, indicative of the angiogenic nature of lower-grade and especially high-grade brain tumours. Moreover, these findings unravelled the top differentially regulated pathways (belonging to five major groups, namely angiogenesis-related pathways, development and NVL molecules, cell–cell and cell–ECM interactions, immune-related processes and metabolism) in both fetal and pathological brain ECs as compared with healthy adult brain ECs. Most interestingly, more than half of the differentially regulated pathways in pathological brain ECs also showed differential regulation in fetal brain ECs163. This observation was also made in both low-grade and high-grade gliomas, with the reactivated pathways belonging to the five canonical groups listed above.
In summary, these results showed that, in the human brain, pathological ECs share common hallmarks across various diseases, including brain tumours and brain vascular malformations. Comparison of fetal and pathological ECs also suggested that signalling pathways regulating vascular growth during fetal brain development are silenced in adulthood and subsequently activated again in the vasculature of brain tumours and brain vascular malformations, thereby highlighting the potential importance of developmental pathways in various vascular-dependent brain pathologies. Notably, the observed similarities between fetal and pathological brain ECs at the level of active signalling pathways (for example, reactivated developmental pathways versus persistence of a less differentiated cell type) as well as their functional importance are currently incompletely understood and warrant further investigation.
A developmental look at glial brain tumours
From surgical and neuroradiological observations, glial brain tumours are frequently confined to specific brain regions (Fig. 5), as illustrated by gliomas largely having a gyral or subgyral locatation268,269. Low-grade gliomas (from which many high-grade gliomas arise) are typically confined to a gyrus while respecting pial borders, rarely crossing sulci268,270 (Fig. 5a,c), but the cellular and molecular mechanisms underlying these observations are unknown. In light of compartment-specific embryonic vascular development6,56, it is intriguing to speculate that the restriction of the brain tumour extension within defined gyri might, at least partially, be due to its territorial vascular supply. Interestingly, upon malignant transformation of a low-grade glioma to a high-grade glioma, the tumour mass often spreads on a radial axis, crossing sulci and extending to adjacent gyri270 (Fig. 5b,c).
Strikingly, this brain tumour extension or progression looks comparable to the axis of brain AVM growth towards the ventricle, with infiltration along white matter tracts, such as the corpus callosum and subgyral short association fibres270,271 (Fig. 6). As long as glial tumours are localized within gyri and respect the sulcal borders, their blood supply is thought to be provided by neovessels forming via sprouting angiogenesis from pre-existing arteries running within the sulci271. High-grade gliomas crossing these borders may find ways to break those boundaries and recruit neovessels from adjacent sulci or gyri (for example, via CNS-specific and/or general reactivated NVL molecules or endothelial metabolism cues) via sprouting angiogenesis and other modes of vessel formation (Fig. 1), but this intriguing hypothesis needs further testing.
Angiogenesis in brain AVMs
Brain vascular malformations are characterized by abnormal blood vessel growth and altered maturation of the vessel wall61,162. Here, owing to space limitations, we focus on brain AVMs, which are one of the most commonly encountered brain vascular malformations and are a leading cause of haemorrhage in children and young adults272. Brain AVMs are characterized by aberrant angiogenesis and a malformed capillary bed, thereby representing an exemplar pathology to understand brain vascular biology across arteriovenous zonation273 (Figs. 4e,f and 6). For in-depth discussions of other types of brain vascular malformations, we refer readers to review articles on cerebral cavernous malformations274,275,276, vein of Galen malformations277 and dural arteriovenous fistulas278.
Brain AVMs
High-pressure arterial blood from feeding arteries shunts directly into the low-pressure outflow veins, rendering brain AVMs prone to rupture273. Regarding their potential developmental origin, brain AVMs so far not been detected in utero (via either ultrasound or MRI techniques). As the same detection methods are capable of detecting similarly sized vein of Galen vascular malformations in utero279, brain AVMs might not develop during embryonic or fetal stages of development. Moreover, the existence of more than ten case reports of de novo formation of brain AVMs in children (for example, they are not present on initial postnatal imaging after trauma but are present on subsequent postnatal imaging280) suggests a postnatal rather than a fetal or embryonic origin.
During normal vascular (brain) development, arteries and veins follow a parallel and countercurrent course without direct communication273. They are separated by capillary networks in the respective tissues, and premature arteriovenous connections are prevented by specific developmentally active molecular control systems (involving, for example, COUP transcription factor 2, NRP2, VEGFR3–FLT4 and EphB4 (refs. 273,281,282)). CNS and peripheral AVMs are thought to occur as a consequence of a failure in these control systems273. Whereas the molecular basis of this aberrant arteriovenous separation leading to AVM formation is unclear, genetic AVM syndromes have provided insight into some crucial signalling pathways that govern arteriovenous patterning273,283,284,285.
Hereditary brain and peripheral AVMs
Hereditary haemorrhagic telangiectasia
Hereditary haemorrhagic telangiectasia (HHT), or Osler–Weber–Rendu syndrome, is an autosomal dominant disorder characterized by germ line mutations in genes encoding components of the TGFβ signalling pathway27,273,286. As TGFβ is required in embryonic and postnatal development for the establishment and remodelling of the INVP via molecular regulation of EC proliferation, migration and differentiation as well as of pericyte and vSMC recruitment to newly formed blood vessels, it can be considered an important developmentally active signalling cascade that is reactivated in AVMs14,27,124 (Supplementary Table 2).
Mutations in ENG, encoding a TGFβ co-receptor that potentiates TGFβ signalling27,50, cause HHT type 1 (refs. 287,288) (Fig. 6j). Eng−/− mice die at E11.5 owing to defective (both CNS and non-CNS) vascular development, caused by a lack of functional vSMCs and arrested vascular remodelling130. Thus, ENG is required for both CNS and peripheral vasculogenesis and angiogenesis289. Mutations in ALK1, encoding a type 1 TGFβ receptor that stimulates kinase activity290, cause HHT type 2 (ref. 288) (Fig. 6j). Alk1−/− mice die at E11.5 owing to comparable non-CNS-specific vascular defects such as AVMs in the intra-embryonic aortic endothelium, decreased vSMC coverage and disrupted arterial identity129,291. Mutations in SMAD4, encoding a downstream effector of TGFβ signalling290, lead to the combined syndrome of HHT and juvenile polyposis292 (Fig. 6j).
In addition, BMP9 and BMP10, which are important for vascular brain and retinal development293 and vessel normalization in breast cancer294, bind ALK1 with high affinity and induce downstream SMAD signalling, and their genes are mutated in a vascular anomaly syndrome that has phenotypic overlap with HHT295,296,297 (Fig. 6j). Increasing evidence shows that the BMP9–TGFBR–ENG–ALK1 signalling axis is a developmental (and non-CNS-specific) angiogenic pathway crucially involved in the formation of hereditary AVM syndromes298 (Fig. 6j). Whereas ENG and ALK1 are involved in sprouting angiogenesis during development in a non-CNS-specific manner299, BMP9 and BMP10 are critical for postnatal retinal vascular remodelling and embryonic vascular development inside and outside the CNS293,300.
Differences between mouse models of brain AVMs in adult mice versus developing mice might be due to the dynamic vessel remodelling and highly angiogenic character of the vascular bed during development versus the relatively stable and quiescent nature of the vasculature at the adult stage. Accordingly, in adult mice, regional or tissue-specific CKO of Eng or Alk1 produced AVMs in the lung, brain and gastrointestinal tract but only if angiogenesis was simultaneously stimulated by VEGF301,302,303. This ‘second hit’ theory304 postulates that a genetic predisposition (the first hit) in combination with an angiogenic trigger (for example, a repetitive injury; the second hit) leads to the reactivation of several developmental angiogenic pathways (for example, the TGFβ pathway)303. As HHT-related mutations involve loss of function in TGFβ pathway-linked genes in ECs but AVMs occur in only certain organs affected by these mutations, it may be that TGFβ haploinsufficiency is not sufficient to initiate a brain AVM in adulthood and requires another somatic mutation (a ‘second hit’) affecting the TGFβ pathway.
Accordingly, whereas in the adult mouse, with a stable or quiescent brain vasculature, this second hit is required to initiate brain AVM formation, in the developing (embryonic or postnatal) mouse, with a dynamic or active brain vasculature, brain AVM formation can occur without a second hit303. In about 15% of patients with clinical features of HHT, no mutations in genes encoding components of the TGFβ pathway are found and the origin of the malformation is unknown305.
Capillary malformation–AVM syndrome
Another hereditary genetic syndrome is capillary malformation–AVM syndrome type 1, caused by heterozygous germ line mutations in RASA1, encoding the cytoplasmic protein RasGAP, a negative regulator of the RAS–MAPK signalling pathway crucial for growth regulation and EC and PVC proliferation in various tissues306,307,308,309. RasGAP inactivates RAS by hydrolysing GTP to GDP, thereby negatively regulating the RAS–MAPK signal transduction pathway, with a loss of RasGAP activity resulting in the excessive activation of RAS and downstream signalling pathways295,307,309,310 (Fig. 6j). Mechanistically, RasGAP acts downstream of the endothelial receptor EphB4, a marker of venous endothelial identity and a regulator of developmental and brain tumour angiogenesis, by promoting venous differentiation311. Accordingly, RASA1 mutations result in dysregulation of arteriovenous patterning (with a shift from venous to arterial differentiation) and formation of AVMs inside and outside the CNS310,312. Germ line mutations in EPHB4 have been identified in CM–AVMs that are negative for RASA1 mutations and are therefore categorized as capillary malformation–AVM type 2 (ref. 313).
Sporadic brain and peripheral AVMs
Somatic mutations are increasingly being reported in studies investigating the genetic basis of sporadic (brain) vascular malformations314,315,316,317. Many of these mutations are common non-coding single-nucleotide polymorphisms. For example, non-CNS-specific venous malformations are associated with somatic mutations in PIK3CA and TIE2 (refs. 315,316), lymphatic malformations are associated with mutations in PIK3CA318, Sturge–Weber syndrome, capillary malformations and congenital haemangiomas are linked to GNAQ mutations319,320, verrucous venous malformations are linked to MAP3K3 mutations321, extracranial AVMs are associated with MAP2K1 mutations322 and brain AVMs were recently associated with activating somatic mutations in KRAS162,323,324,325. Other groups studying brain AVMs have reported single-nucleotide polymorphisms located in ALK1 (refs. 326,327), ENG328, IL1B329, ITGB8 (ref. 330), ANGPTL4 (ref. 331), GPR124 (ref. 332), VEGFA333, MMP3 (ref. 334) and MMP9 (ref. 317) (Fig. 6k; see Supplementary Table 2 for additional candidate genes for brain AVM initiation and progression).
Sturge–Weber syndrome is caused by non-hereditary somatic mutations in the protein GNAQ, characterized by port wine stains on the face and leptomeningeal angiomatosis with brain vascular malformations, indicating an underlying general/non-CNS-specific molecular mechanism319. Mutations in GNAQ decrease GTPase activity and increase signalling of associated G proteins, leading to increased MAPK activity319,335 (Fig. 6k and Supplementary Table 2). It remains to be investigated whether genetic risk factors in the context of hereditary AVM syndromes render individuals more susceptible to developing sporadic AVMs.
A key future step in the improvement of the clinical management of brain AVMs would be the development of novel anti-angiogenic therapies336,337, for instance targeting the pathways downstream of KRAS mutations with MEK inhibitors (which are already approved for the treatment of brain tumours338,339) or other targets emanating from single-cell studies75,163,265. For explorations of the future clinical and pharmacological treatment of brain AVMs, we refer readers to recent reviews on this topic336,337.
Developmental pathways in brain AVMs
General molecular mechanisms reactivated in brain AVMs
Interestingly, most of the mutations associated with vascular malformations characterized so far are linked to the RAS–RAF–MAPK and PI3K–PTEN–AKT–mTOR pathways, both of which have pivotal roles in physiological (CNS and non-CNS) vascular development (Fig. 6j,k and Supplementary Table 2). In particular, high-flow AVMs are associated with the latter, as most brain and spinal AVMs have mutations in KRAS162,323,324,325, whereas low-flow vascular malformations are often associated with activating mutations affecting the PI3K pathway314,316. These observations strongly suggest that the RAS–RAF–MAPK pathway is a central signalling node for the development of AVMs in the brain and spinal cord as well as in non-CNS organs. It remains, however, unclear whether and how the BMP9–TGFβ–SMAD pathway involved in HHT-related AVMs (but also somatic mutations, for example, found in ITGB8) and genes affecting the RAS–RAF–MAPK pathway overlap or interact during normal brain vascular development and (CNS and non-CNS) AVM initiation and progression.
Currently, the downstream effector signalling pathways that are required for AVM development are not well characterized in humans but they are hypothesized to be crucial regulators of arteriovenous specification and zonation273. Several AVM mouse models have elucidated underlying molecular mechanisms driving brain AVM initiation and progression340. In particular, manipulation of the developmentally active DLL4–Jagged–Notch pathway resulted in the development of (CNS and non-CNS) vascular malformations in mice340. Whereas genetic ablation of both Notch1 and Notch4 resulted in embryonic lethality, haploinsufficiency of Dll4 induced AVM-like brain (and non-CNS, including dorsal aorta and cardinal veins) lesions at the embryonic stage that were characterized by the lack of a capillary bed between feeding arteries and draining veins341.
At the postnatal stage, endothelial-specific inducible postnatal expression of constitutively active NOTCH4 induced brain AVMs in mice342, which resulted from the increase in length and calibre, and not the absence, of brain capillaries343. Strikingly, these AVMs were reversible upon normalization of NOTCH4 expression342. vSMCs and ECs in human brain AVMs exhibited upregulated DLL4–Jagged–NOTCH1 signalling compared with healthy cerebral vessels344, indicating that NOTCH1 signalling contributes to the development of human brain AVMs. In arteriovenous differentiation of ECs during development, NOTCH1 and NOTCH4 are major determinants of arterial fate choice, associated with expression of the arterial markers ephrin B2, CXCR4 and connexin 40 (ref. 345). Lack of Notch signalling results in a default phenotype characterized by venous markers such as COUP transcription factor 2, NRP2 and VEGFR3 and the receptor EphB4 (refs. 281,282). Furthermore, activating mutations in RAS–RAF–MAPK pathway genes would result in constitutively active and VEGF-independent activation of the Notch pathway. Indeed, expression of mutant active KRAS in ECs results in overexpression of the Notch pathway and angiogenic cascades downstream of VEGF162 along with endothelial-to-mesenchymal transition. At a cellular level, mutant KRAS induced a migratory phenotype of brain (and peripheral) ECs, loss of tight junctions and disorganization of cytoskeletal actin with intact proliferation162.
A better understanding of the signalling downstream of the RAS–RAF–MAPK and PI3K–PTEN–AKT–mTOR pathways during normal vascular development in CNS and non-CNS tissues and in AVMs may help to develop a more comprehensive picture of arteriovenous morphogenesis. A recent study addressed endothelial aberrancy in brain AVMs at the single-cell level, linking the transcriptional state of ECs isolated from human brain AVMs to a dysregulation of arteriovenous zonation, evidenced by a strong enrichment of arterial and venous transcriptional identity but not of capillary or venule transcriptional identity75. That study further found an upregulation of PLVAP (a marker of fenestrated endothelium75) and the pro-angiogenic protein PGF in the AVM nidus75.
Along those lines, in our own scRNA-seq dataset, we found upregulated PLVAP predominantly in angiogenic capillary ECs of brain AVMs as well as reactivated fetal signalling pathways in human AVMs with a general (non-CNS-specific) mode of action, involving the integrin, TGFβ, angiopoietin–TIE, epithelial-to-mesenchymal transition-related, inflammatory-related and IL4-mediated signalling cascades163.
CNS-specific molecular mechanisms in brain AVMs
Most of the molecules involved in vascular brain development that are reactivated in brain AVMs act via a general (non-CNS-specific) mechanism of action (Fig. 6j,k and Supplementary Table 2). Interestingly, somatic mutations in the gene encoding the CNS-specific angiogenesis regulator GPR124 were identified in human brain AVMs. This finding, however, could not be substantiated in a replication cohort or meta-analysis of individuals with brain AVMs332.
Molecular mechanisms in brain AVM vasculature at the single-cell level
scRNA-seq allows the study of the biology of brain vascular malformations (including brain AVMs) at the single-cell level75,346,347, yielding insights into EC and PVC heterogeneity, their interactions in the blood vessel microenvironment, the intermediate cell types that arise during blood and lymphatic vessel development, and cell type-specific responses to disease347.
Recently, Winkler and colleagues presented a human cerebrovascular cell atlas that compared isolated cells from the adult human brain with cells isolated from resected human brain AVM tissue75. They uncovered a previously unknown heterogeneity in PVCs, revealed transcriptional variation within SMCs and perivascular fibroblasts, and identified SMC-like cells known as fibromyocytes75. In addition to a loss of physiological arteriovenous zonation, which is characteristic of brain AVM pathology, they reported a distinct transcriptomic state in a subset or cluster of ECs relating to heightened angiogenic potential and immunogenicity, indicating that this subset of ECs may originate from the AVM nidus75.
In our molecular single-cell atlas, we found an increase in the number of venous EC clusters in brain AVMs and cavernomas compared with adult control brain tissue163, suggesting an involvement of venous ECs in the pathophysiology of brain vascular malformations, as reported for cavernomas in mice346. Similarly to the situation observed in glial brain tumours, we identified alteration of arteriovenous differentiation and CNS-specific properties, upregulation of major histocompatibility complex class II molecules and reactivated developmental pathways in brain AVMs (although these were less numerous than those in brain tumours) belonging to the aforementioned five major groups of pathways163, indicating some common mechanisms across brain tumours and brain vascular malformations163.
Although shared signalling pathways seem to regulate vascular growth in brain pathologies (including brain tumours and brain vascular malformations) and in the fetal brain, it remains to be clarified whether the pathways observed in brain pathologies are reactivated developmental pathways or rather reflect the persistence (for example, the presence since development) of a less differentiated cell type (or even a combination of these two). Moreover, the functional relevance of these developmental pathways in vascular-dependent brain pathologies is not clear, and further studies will be needed to elucidate their translational potential in terms of developing therapies targeting the vasculature in brain tumours and brain vascular malformations. Single-cell atlases such as those discussed above will inform such endeavours347.
A developmental look at brain AVMs
On the basis of neuroradiological and surgical observations, most brain AVMs occupy a defined segment of the brain’s vascular tree and do not grow after diagnosis273,348,349. It is currently thought that AVMs develop during early postnatal life, at highly active developmental stages, as mentioned earlier herein (Fig. 6a–i). Postnatal development of brain AVMs is supported by the lack of cases reported in utero (which indicates an embryonic AVM development). However, this does not exclude the possibility that somatic mutations and brain AVM initiation occur during embryonic development but remain undetectable until later stages of postnatal life. KRAS mutations seem restricted to the endothelium in brain AVMs, suggesting that somatic mutations occurring in progenitor ECs will ‘trace’ the future developmental territory (for example, the vascular network field) of their daughter ECs. Accordingly, large brain AVMs would result from somatic mutations occurring early in development (spanning larger vascular territories) (Fig. 6a–d), whereas small AVMs may reflect later mutations spanning a restricted vascular territory (Fig. 6e–h). Strikingly, many brain AVMs spread preferentially along a radial axis extending from the ventricles to the pial cortical surface. When small, they can be constrained in and around the pial, sulcal and cortical areas or alternatively in the ventricular, ependymal and subependymal zones (for example, choroidal AVMs), but they do not occur isolated midway in the white matter without reaching either the cortical surface or the ventricular surface (Fig. 6a–i). These observations prompt a comparison with the radial ventriculocortical axis of the radial glia and cortical neuron migration as well as of sprouting angiogenesis during embryonic and postnatal brain vascular development and maturation (Fig. 3). Could somatic mutations in EC progenitors actually be genetic tracers of the migrating and dividing EC progenitors recruited in sprouting angiogenesis and could brain AVMs, consequently, be an aberrant, dysmorphic and oversized capillary network occupying a developmentally defined vascular zone? This tempting but speculative hypothesis may clarify the temporo-spatial organization of sprouting angiogenesis in the developing CNS vascular network and developmental morphogenesis of brain AVMs.
Perspectives and conclusion
Several outstanding questions exist regarding the cellular and molecular mechanisms and the EC and PVC heterogeneity that underlie the brain vasculature during brain development, in the adult healthy brain and in vascular-dependent CNS pathologies and the shared angiogenic pathways between brain development and pathologies. First, how do CNS-specific and general cues interact molecularly to govern CNS angiogenesis during embryological and postnatal brain development and in vascular-dependent CNS pathologies? The CNS-specific cues that are known to regulate developmental angiogenesis show striking region specificity (for example, between the hindbrain and the forebrain)133,135,136,148. Moreover, brain region-specific intrinsic transcription factors were shown to govern embryonic brain angiogenesis in a spatially regulated manner6. These are interesting observations that lead to the question of whether region-specific vascular growth might be linked to region-specific brain function during development and in disease. Furthermore, both glial brain tumours and brain AVMs are most often confined to specific brain regions, but whether CNS-specific and region-specific regulators6 of angiogenesis participate in the molecular mechanisms underlying these observations, suggestive of another link between the developmental brain vasculature and the pathological brain vasculature, remains unknown.
All currently known molecules and signalling pathways underlying hereditary AVM syndromes and sporadic brain AVMs characterized by somatic mutations are non-CNS-specific regulators of angiogenesis162,287,288,323,325,328 (although the CNS-specific signalling receptor GPR124 is expressed in brain AVM ECs332, a functional role for it in brain AVM has not been established to date). The lack of CNS specificity in this signalling is in line with the fact that multiple organs are affected by AVMs in these syndromes. Regarding sporadic AVMs, KRAS and BRAF mutations in ECs cause brain and spinal cord AVMs (peripheral AVMs were not reported)162,323,325, whereas RAS and MAPK variants cause sporadic brain AVMs and skin vascular malformations350, indicating specificity for neuroectodermal-derived tissues. Given the highly specialized vasculature of the CNS9 and the observed alteration of the CNS-specific gene profile in pathological brain ECs (for example, pathological brain ECs partially acquiring a gene profile that is characteristic of peripheral or non-CNS ECs)163, we think that the role of CNS-specific and general regulators of angiogenesis in brain tumours, brain AVMs and other CNS pathologies warrants further investigation. For instance, conducting single-cell multi-omics studies of the vasculature in different compartments of the developing brain as well as of brain region-confined pathologies (for example, brain tumours in defined gyri, for instance superior temporal lobe glioblastoma351) will be an important step forward to elucidate these very exciting concepts.
The second question is how different or comparable are the mechanisms governing angiogenesis during brain development, in brain tumours and in brain AVMs, and how can this be addressed by single-cell analyses in the multi-omics era? Currently, it remains incompletely understood to what extent developmental signalling pathways reactivated in pathologies differ from those active during (brain) development. Regulatory effects of neurodevelopmental programmes in glioblastoma cells267 as well as oncofetal reprogramming of ECs in hepatocellular carcinoma have been reported in single-cell studies352, but the relevance of fetal pathways in the pathological brain vasculature has not been described so far. Therefore, direct comparison between ECs derived from developing (fetal or embryonic or postnatal) brains, ECs derived from healthy adult control brains and ECs derived from vascular-dependent CNS pathologies at single-cell resolution is of crucial importance.
Recently, the power of single-cell analyses enabled us to unravel key signalling pathways in brain ECs active during development that were reactivated in brain tumour and brain vascular malformation ECs163. Our finding that more than half of all regulated pathways in pathological ECs are of developmental origin confirm a paradigm in which signalling axes driving vascular growth during fetal human brain development are silenced in the adult human control brain and (re)activated across various human brain pathologies, including various brain tumours and brain vascular malformations163. The crucial importance of developmental pathways in vascular-dependent brain pathologies and the suggested functional plasticity of ECs353,354 across developmental and disease states will need to be functionally validated using emerging novel techniques such as single-cell genomics355, spatial transcriptomics (for example, Slide-seq356 or other spatial transcriptomics techniques357) and single-cell proteomics (for example, imaging mass cytometry358, single-cell cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq)359, and single-cell western blotting360). These techniques provide exciting novel avenues allowing direct measurement of RNA and protein expression in isolated human brain ECs (and PVCs of the NVU), thereby providing insights into the molecular and genetic basis while retaining spatial information of both developmental and pathological CNS angiogenesis using an unbiased approach. These cellular and molecular insights at single-cell precision leading to the identification of novel molecular angiogenic signalling cascades then need to be studied using in vivo models of angiogenesis for both CNS (brain, spinal cord and retina) and non-CNS tissues/organs using xenograft models and other strategies361,362,363.
The third crucial question for future studies is can single-cell multi-omics techniques be used to further clarify the role of inflammatory or immune-related processes in pathological angiogenesis beyond what is currently known (for example, inflammation-induced pro-angiogenic effects on the vasculature in brain tumours and brain vascular malformations364,365,366)? Notably, recent single-cell studies have further emphasized additional roles of inflammatory processes in pathological ECs across various brain diseases, including brain AVMs75,163, brain tumours163 and neurodegenerative diseases367,368,369. Interestingly, pathological ECs show upregulation of inflammatory or immune-related pathways and of major histocompatibility complex class II molecules in brain tumours (including glial brain tumours) and brain vascular malformations (including brain AVMs)75,163 as well as elevated levels of immune cell–EC interactions in brain tumours (including glial brain tumours) and brain vascular malformations (including brain AVMs)163 as well as in Alzheimer disease and Huntington disease367,368. These very interesting observations warrant further investigation at both the single-cell level and the functional level, with potentially crucial implications for both basic biological understanding and translational settings.
The fourth question is how important are NVL-related developmental pathways for pathological brain angiogenesis, and are they of a CNS-specific nature or a general nature? We anticipate that addressing the role of NVL molecules in ECs and PVCs within the developing and the pathological CNS (for example, through leveraging single-cell multi-omics techniques163,370,371,372) will provide important insights that have to be characterized at multiple organizational levels.
At the molecular level, NVL-related pathways are of crucial importance during vascular brain development, and many are reactivated in vascular brain pathologies, as evidenced by our recent single-cell atlas9,12,14,79,373. As the cellular and molecular interaction and bilateral crosstalk between neuronal and vascular tissue are especially tight in the CNS9,14,374, we reason that NVL molecules (being of a general or a CNS-specific nature) are of crucial importance in the healthy and the diseased brain and need to be studied in more detail in the future.
Regarding the layered organization of the human brain375, neurovascular interactions might be fundamentally different in distinct CNS compartments, with predominantly neuron-to-EC interactions in CNS grey matter and mainly oligodendrocyte-to-EC interactions in the CNS white matter, both involving classic and non-classic axon guidance cues9.
Members of the classic axonal guidance and NVL molecule families such as netrins, semaphorins, ephrins and Slit proteins, and their receptors, as well as non-classic axon guidance and NVL molecules such as WNT proteins, SHH and BMPs are implicated in arteriovenous differentiation14,15,163,201,374,376. NVL molecules interact with the Notch pathway9, and interactions between NVL molecules and Notch are important in arteriovenous differentiation9,14,201. Most notably, NOTCH1 and NOTCH4 are major drivers of arterial fate, associated with expression of the arterial markers ephrin B2, CXCR4 and connexin 40 (ref. 345). Lack of Notch signalling results in upregulation of venous markers such as COUP transcription factor 2, NRP2, VEGFR3 and the receptor EphB4 (refs. 75,281,282). It remains to be explored how NVL molecules contribute to these phenomena, and analyses of NVL molecules and pathways in distinct arteriovenous compartments at the single-cell level75,163,367,368 comprise a promising approach.
The final question is as follows: given the current focus on sprouting angiogenesis, how important are other modes of vessel formation during brain development, in brain tumours and in brain AVMs, how do they differ between distinct vascular beds inside and outside the CNS and how are they regulated at the molecular level? Modes of vessel formation other than sprouting angiogenesis probably have roles in both brain development and vascular-dependent brain pathologies24. Vasculogenesis is important during PNVP formation, whereas the INVP is predominantly vascularized by sprouting angiogenesis27, but the involvement of other modes of vessel formation during these developmental stages remains to be determined. In tumours located inside and outside the CNS, GSC transdifferentiation into tumour ECs20,21,215 or tumour pericytes22 directly involves PVCs of the NVU. Similarly, vascular co-option and mimicry in liver cancer exemplifies PVC–EC interactions outside the CNS173. The molecular mechanisms underlying vascular co-option, vascular mimicry and vascular intussusception remain largely unexplored. A more thorough investigation of the influence of PVCs and cellular interactions within the NVU in the setting of these additional modes of neovascularization using single-cell sequencing (for example, scRNA-seq377 and CITE-seq359) and imaging (for example, fluorescence light sheet microscopy and high-throughput microscopy378) techniques is key for future progress in developmental and pathological settings.
In conclusion, it has become increasingly evident that the remarkable cellular heterogeneity and molecular heterogeneity of the human brain vasculature within and between individuals across development and disease as well as its specific characteristics, such as CNS specificity and arteriovenous zonation, require thorough characterization at the single-cell level. Furthermore, a clearer mechanistic understanding of the silencing of developmentally active angiogenic processes in the healthy adult brain and subsequent reactivation in disease at the single-cell level will be crucial for the development of future therapies aimed at targeting vascular pathology. We anticipate that the constantly evolving multi-omics approaches (including scDNA-seq, single-cell assay for transposase-accessible chromatin with sequencing (scATAC-seq), imaging cytometry by time of flight and spatial transcriptomics) will enable various long-standing questions in the field of neurovascular biology to be answered and will continue to increase our knowledge of the human brain vasculature in development, adulthood and disease.
References
Mink, J. W., Blumenschine, R. J. & Adams, D. B. Ratio of central nervous system to body metabolism in vertebrates: its constancy and functional basis. Am. J. Physiol. 241, R203–R212 (1981).
Zlokovic, B. V. & Apuzzo, M. L. Strategies to circumvent vascular barriers of the central nervous system. Neurosurgery 43, 877–878 (1998).
Wälchli, T. et al. Quantitative assessment of angiogenesis, perfused blood vessels and endothelial tip cells in the postnatal mouse brain. Nat. Protoc. 10, 53–74 (2015). This study describes a method allowing the visualization and quantitative assessment of angiogenesis, ETCs and perfused blood vessels in the postnatal mouse brain.
Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178–201 (2008). This review provides an in-depth exploration of BBB integrity, its cellular and molecular composition, and its disruption in neurodegenerative disorders such as Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and multiple sclerosis.
Stewart, P. A. & Wiley, M. J. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail–chick transplantation chimeras. Dev. Biol. 84, 183–192 (1981).
Vasudevan, A., Long, J. E., Crandall, J. E., Rubenstein, J. L. & Bhide, P. G. Compartment-specific transcription factors orchestrate angiogenesis gradients in the embryonic brain. Nat. Neurosci. 11, 429–439 (2008). This study demonstrates that telencephalic angiogenesis in mice progresses along a spatial, ventral-to-dorsal gradient regulated by compartment-specific homeobox transcription factors in addition to passive sprouting into the brain parenchyma upon metabolic needs.
Komsany, A. & Pezzella, F. in Tumor Vascularization (eds Ribatti, D. & Pezzella, F.) 113–127 (Academic Press, 2020).
Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).
Wälchli, T. et al. Wiring the vascular network with neural cues: a CNS perspective. Neuron 87, 271–296 (2015). This review focuses on the regulatory effects of molecules involved in the NVL on angiogenesis in both peripheral tissues and the CNS, while distinguishing between general and CNS-specific cues for angiogenesis.
Muoio, V., Persson, P. B. & Sendeski, M. M. The neurovascular unit – concept review. Acta Physiol. 210, 790–798 (2014).
Eichmann, A. & Thomas, J. L. Molecular parallels between neural and vascular development. Cold Spring Harb. Perspect. Med. 3, a006551 (2013).
Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298–307 (2011).
Jain, R. K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26, 605–622 (2014).
Paredes, I., Himmels, P. & Ruiz de Almodovar, C. Neurovascular communication during CNS development. Dev. Cell 45, 10–32 (2018).
Quaegebeur, A., Lange, C. & Carmeliet, P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 71, 406–424 (2011).
Carmeliet, P. & Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature 436, 193–200 (2005).
Wälchli, T. et al. Nogo-A is a negative regulator of CNS angiogenesis. Proc. Natl Acad. Sci. USA 110, E1943 (2013).
Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873–887 (2011).
Ferguson, J. E. 3rd, Kelley, R. W. & Patterson, C. Mechanisms of endothelial differentiation in embryonic vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 25, 2246–2254 (2005).
Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824–828 (2010). This study shows that a variable number of endothelial cells in glioblastoma carry the same genomic alteration as tumour cells, indicating that a significant portion of the vascular endothelium is of neoplastic origin, describing a new mechanism for tumour vasculogenesis that may explain the presence of cancer-derived endothelial-like cells in several malignancies.
Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829–833 (2010). This study demonstrates that a subpopulation of glioblastoma-derived ECs harbour the same somatic mutations identified in tumour cells and shows that the stem-cell-like CD133+ fraction includes a subset of VE-cadherin-expressing cells, indicative of transdifferentiation of tumour-derived stem cells into EPCs capable of maturing into ECs, thereby contributing to the tumour vasculature.
Cheng, L. et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139–152 (2013).
Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020).
Jain, R. K. & Carmeliet, P. SnapShot: tumor angiogenesis. Cell 149, 1408–1408.e1401 (2012).
Hardee, M. E. & Zagzag, D. Mechanisms of glioma-associated neovascularization. Am. J. Pathol. 181, 1126–1141 (2012).
Boire, A., Brastianos, P. K., Garzia, L. & Valiente, M. Brain metastasis. Nat. Rev. Cancer 20, 4–11 (2020).
Vallon, M., Chang, J., Zhang, H. & Kuo, C. J. Developmental and pathological angiogenesis in the central nervous system. Cell. Mol. Life Sci. 71, 3489–3506 (2014).
Lee, H. W. et al. Role of venous endothelial cells in developmental and pathologic angiogenesis. Circulation 144, 1308–1322 (2021).
Hellstrom, M., Phng, L. K. & Gerhardt, H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh. Migr. 1, 133–136 (2007).
Blanco, R. & Gerhardt, H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med. 3, a006569 (2013).
Xue, Y. et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet. 8, 723–730 (1999).
Jakobsson, L. et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 12, 943–953 (2010). This study illustrates that ECs compete for the tip cell position through relative levels of VEGFR1 and VEGFR2, in the presence of Notch-modulated DLL4 expression.
Bentley, K. et al. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nat. Cell Biol. 16, 309–321 (2014).
Pitulescu, M. E. et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat. Cell Biol. 19, 915–927 (2017).
Hellstrom, M. et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776–780 (2007).
Shah, A. V. et al. The endothelial transcription factor ERG mediates angiopoietin-1-dependent control of Notch signalling and vascular stability. Nat. Commun. 8, 16002 (2017).
Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464–478 (2007).
Herbert, S. P. & Stainier, D. Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551–564 (2011).
Ali, Z. et al. Intussusceptive vascular remodeling precedes pathological neovascularization. Arterioscler. Thromb. Vasc. Biol. 39, 1402–1418 (2019).
Djonov, V., Baum, O. & Burri, P. H. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res. 314, 107–117 (2003).
Patan, S., Alvarez, M. J., Schittny, J. C. & Burri, P. H. Intussusceptive microvascular growth: a common alternative to capillary sprouting. Arch. Histol. Cytol. 55, 65–75 (1992).
Patan, S., Haenni, B. & Burri, P. H. Evidence for intussusceptive capillary growth in the chicken chorio-allantoic membrane (CAM). Anat. Embryol. 187, 121–130 (1993).
Makanya, A. N., Stauffer, D., Ribatti, D., Burri, P. H. & Djonov, V. Microvascular growth, development, and remodeling in the embryonic avian kidney: the interplay between sprouting and intussusceptive angiogenic mechanisms. Microsc. Res. Tech. 66, 275–288 (2005).
Gargett, C. E. & Rogers, P. A. Human endometrial angiogenesis. Reproduction 121, 181–186 (2001).
Djonov, V., Schmid, M., Tschanz, S. A. & Burri, P. H. Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ. Res. 86, 286–292 (2000).
Zhang, Z. G. et al. Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 22, 379–392 (2002).
Nico, B. et al. Intussusceptive microvascular growth in human glioma. Clin. Exp. Med. 10, 93–98 (2010).
Ornelas, S. et al. Three-dimensional ultrastructure of the brain pericyte-endothelial interface. J. Cereb. Blood Flow. Metab. 41, 2185–2200 (2021).
Hartmann, D. A. et al. Brain capillary pericytes exert a substantial but slow influence on blood flow. Nat. Neurosci. 24, 633–645 (2021).
Mancuso, M. R., Kuhnert, F. & Kuo, C. J. Developmental angiogenesis of the central nervous system. Lymphat. Res. Biol. 6, 173–180 (2008).
Iadecola, C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 96, 17–42 (2017).
Tam, S. J. & Watts, R. J. Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu. Rev. Neurosci. 33, 379–408 (2010).
Sweeney, M. D., Ayyadurai, S. & Zlokovic, B. V. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat. Neurosci. 19, 771–783 (2016).
Daneman, R., Zhou, L., Kebede, A. A. & Barres, B. A. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468, 562–566 (2010).
Johansson, P. A. et al. Blood-CSF barrier function in the rat embryo. Eur. J. Neurosci. 24, 65–76 (2006).
Saunders, A. et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015–1030.e1016 (2018).
Saunders, N. R. et al. The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history. Front. Neurosci. 8, 404–404 (2014).
Saunders, N. R., Liddelow, S. A. & Dziegielewska, K. M. Barrier mechanisms in the developing brain. Front. Pharmacol. 3, 46 (2012).
Ek, C. J., Dziegielewska, K. M., Stolp, H. & Saunders, N. R. Functional effectiveness of the blood-brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). J. Comp. Neurol. 496, 13–26 (2006).
Zhao, Z., Nelson, A. R., Betsholtz, C. & Zlokovic, B. V. Establishment and dysfunction of the blood-brain barrier. Cell 163, 1064–1078 (2015).
Storkebaum, E., Quaegebeur, A., Vikkula, M. & Carmeliet, P. Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nat. Neurosci. 14, 1390–1397 (2011).
Segarra, M., Aburto, M. R. & Acker-Palmer, A. Blood-brain barrier dynamics to maintain brain homeostasis. Trends Neurosci. https://doi.org/10.1016/j.tins.2020.12.002 (2021).
Munji, R. N. et al. Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module. Nat. Neurosci. 22, 1892–1902 (2019).
Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163–1177 (2003).
Tessier-Lavigne, M. & Goodman, C. S. The molecular biology of axon guidance. Science 274, 1123–1133 (1996).
Lowery, L. A. & Van Vactor, D. The trip of the tip: understanding the growth cone machinery. Nat. Rev. Mol. Cell Biol. 10, 332–343 (2009).
Marin-Padilla, M. Early vascularization of the embryonic cerebral cortex: Golgi and electron microscopic studies. J. Comp. Neurol. 241, 237–249 (1985).
Phng, L. K., Stanchi, F. & Gerhardt, H. Filopodia are dispensable for endothelial tip cell guidance. Development 140, 4031–4040 (2013).
del Toro, R. et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116, 4025–4033 (2010).
Zhao, Q. et al. Single-cell transcriptome analyses reveal endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res. 78, 2370–2382 (2018).
Strasser, G. A., Kaminker, J. S. & Tessier-Lavigne, M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 115, 5102–5110 (2010).
Rocha, S. F. et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability. Circ. Res. 115, 581–590 (2014).
Goveia, J. et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37, 21–36.e13 (2020).
Kalucka, J. et al. Single-cell transcriptome atlas of murine endothelial cells. Cell 180, 764–779.e720 (2020). This study presents a comprehensive EC atlas inventorying EC heterogeneity of more than 32,000 single-cell EC transcriptomes from 11 mouse tissues, identifying 78 EC subclusters, combined with in-depth metabolic transcriptome analysis, thereby providing a powerful discovery tool and resource.
Winkler, E. A. et al. A single-cell atlas of the normal and malformed human brain vasculature. Science 375, eabi7377 (2022). This study profiles single-cell transcriptomes of 181,388 cells from fresh human tissue to define a cell atlas of the adult human cerebrovasculature, including EC molecular signatures with arteriovenous segmentation and expanded PVC diversity, enabling detailed comparison of the physiological brain vasculature (from fresh human temporal lobe tissue) with cellular and molecular perturbations in brain AVMs.
Vanlandewijck, M. et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475–480 (2018). This study uses vascular single-cell transcriptomics to provide molecular definitions for the principal types of blood vascular and vessel-associated cells in the adult mouse brain, thereby uncovering the transcriptional basis of the gradual phenotypic zonation along the arteriovenous axis and revealing previously unknown cell type differences.
Segarra, M., Aburto, M. R., Hefendehl, J. & Acker-Palmer, A. Neurovascular interactions in the nervous system. Annu. Rev. Cell Dev. Biol. 35, 615–635 (2019).
Charron, F. & Tessier-Lavigne, M. The Hedgehog, TGF-beta/BMP and Wnt families of morphogens in axon guidance. Adv. Exp. Med. Biol. 621, 116–133 (2007).
Zacchigna, S., Lambrechts, D. & Carmeliet, P. Neurovascular signalling defects in neurodegeneration. Nat. Rev. Neurosci. 9, 169–181 (2008).
Walchli, T. et al. Nogo-A regulates vascular network architecture in the postnatal brain. J. Cereb. Blood Flow. Metab. 37, 614–631 (2017).
Li, W. et al. Peripheral nerve-derived CXCL12 and VEGF-A regulate the patterning of arterial vessel branching in developing limb skin. Dev. Cell 24, 359–371 (2013).
Honma, Y. et al. Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. Neuron 35, 267–282 (2002).
Makita, T., Sucov, H. M., Gariepy, C. E., Yanagisawa, M. & Ginty, D. D. Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons. Nature 452, 759–763 (2008).
Ma, S., Kwon, H. J., Johng, H., Zang, K. & Huang, Z. Radial glial neural progenitors regulate nascent brain vascular network stabilization via inhibition of Wnt signaling. PLoS Biol. 11, e1001469 (2013).
Minocha, S. et al. NG2 glia are required for vessel network formation during embryonic development. eLife 4, e09102 (2015).
Ma, S., Kwon, H. J. & Huang, Z. A functional requirement for astroglia in promoting blood vessel development in the early postnatal brain. PLoS ONE 7, e48001 (2012).
Coelho-Santos, V. & Shih, A. Y. Postnatal development of cerebrovascular structure and the neurogliovascular unit. Wiley Interdiscip. Rev. Dev. Biol. 9, e363 (2020).
Fantin, A., Vieira, J. M., Plein, A., Maden, C. H. & Ruhrberg, C. The embryonic mouse hindbrain as a qualitative and quantitative model for studying the molecular and cellular mechanisms of angiogenesis. Nat. Protoc. 8, 418–429 (2013).
Puelles, L. et al. Patterned vascularization of embryonic mouse forebrain, and neuromeric topology of major human subarachnoidal arterial branches: a prosomeric mapping. Front. Neuroanat. 13, 59 (2019).
Marín-Padilla, M. The human brain intracerebral microvascular system: development and structure. Front. Neuroanat. https://doi.org/10.3389/fnana.2012.00038 (2012).
Pereda, J., Sulz, L., San Martin, S. & Godoy-Guzman, C. The human lung during the embryonic period: vasculogenesis and primitive erythroblasts circulation. J. Anat. 222, 487–494 (2013).
Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K. S. Liver organogenesis promoted by endothelial cells prior to vascular function. Science 294, 559–563 (2001).
Benedito, R. et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137, 1124–1135 (2009).
Leslie, J. D. et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839–844 (2007).
Wang, X. et al. YAP/TAZ Orchestrate VEGF signaling during developmental angiogenesis. Dev. Cell 42, 462–478.e467 (2017).
Hackett, S. F., Wiegand, S., Yancopoulos, G. & Campochiaro, P. A. Angiopoietin-2 plays an important role in retinal angiogenesis. J. Cell Physiol. 192, 182–187 (2002).
Sato, T. N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70–74 (1995).
Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171–1180 (1996).
Jones, C. A. et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat. Cell Biol. 11, 1325–1331 (2009).
Bedell, V. M. et al. roundabout4 is essential for angiogenesis in vivo. Proc. Natl Acad. Sci. USA 102, 6373–6378 (2005).
Tong, M., Jun, T., Nie, Y., Hao, J. & Fan, D. The role of the Slit/Robo signaling pathway. J. Cancer 10, 2694–2705 (2019).
Gu, C. et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 307, 265–268 (2005).
Lejmi, E. et al. Netrin-4 promotes mural cell adhesion and recruitment to endothelial cells. Vasc. Cell 6, 1 (2014).
Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487–491 (2010).
McCarty, J. H. et al. Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development 132, 165–176 (2005).
Elaimy, A. L. & Mercurio, A. M. Convergence of VEGF and YAP/TAZ signaling: implications for angiogenesis and cancer biology. Sci. Signal. https://doi.org/10.1126/scisignal.aau1165 (2018).
Jeansson, M. et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Invest. 121, 2278–2289 (2011).
Zhang, Y., Kontos, C. D., Annex, B. H. & Popel, A. S. Angiopoietin-Tie signaling pathway in endothelial cells: a computational model. iScience 20, 497–511 (2019).
Park, K. W. et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev. Biol. 261, 251–267 (2003).
Dai, C., Gong, Q., Cheng, Y. & Su, G. Regulatory mechanisms of Robo4 and their effects on angiogenesis. Biosci. Rep. https://doi.org/10.1042/bsr20190513 (2019).
Serini, G. et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424, 391–397 (2003).
Vieira, J. M., Schwarz, Q. & Ruhrberg, C. Selective requirements for NRP1 ligands during neurovascular patterning. Development 134, 1833–1843 (2007).
Gu, C. et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5, 45–57 (2003).
Fantin, A. et al. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 121, 2352–2362 (2013).
Zygmunt, T. et al. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev. Cell 21, 301–314 (2011).
van der Zwaag, B. et al. PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Dev. Dyn. 225, 336–343 (2002).
Fukushima, Y. et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J. Clin. Invest. 121, 1974–1985 (2011).
Kim, J., Oh, W. J., Gaiano, N., Yoshida, Y. & Gu, C. Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. Genes Dev. 25, 1399–1411 (2011).
Lejmi, E. et al. Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proc. Natl Acad. Sci. USA 105, 12491–12496 (2008).
Larrivee, B. et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev. 21, 2433–2447 (2007).
Lambert, E., Coissieux, M.-M., Laudet, V. & Mehlen, P. Netrin-4 acts as a pro-angiogenic factor during zebrafish development. J. Biol. Chem. 287, 3987–3999 (2012).
Pasquale, E. B. The Eph family of receptors. Curr. Opin. Cell Biol. 9, 608–615 (1997).
Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165–180 (2010).
Zhang, Y. & Yang, X. The roles of TGF-β signaling in cerebrovascular diseases. Front. Cell Dev. Biol. 8, 567682 (2020).
McCarty, J. H. et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol. Cell. Biol. 22, 7667–7677 (2002).
Zhu, J. et al. beta8 integrins are required for vascular morphogenesis in mouse embryos. Development 129, 2891–2903 (2002).
Arnold, T. D. et al. Excessive vascular sprouting underlies cerebral hemorrhage in mice lacking αVβ8-TGFβ signaling in the brain. Development 141, 4489–4499 (2014).
Hirota, S. et al. Neuropilin 1 balances β8 integrin-activated TGFβ signaling to control sprouting angiogenesis in the brain. Development 142, 4363–4373 (2015).
Oh, S. P. et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl Acad. Sci. USA 97, 2626–2631 (2000).
Li, D. Y. et al. Defective angiogenesis in mice lacking endoglin. Science 284, 1534–1537 (1999).
Anderson, K. D. et al. Angiogenic sprouting into neural tissue requires Gpr124, an orphan G protein-coupled receptor. Proc. Natl Acad. Sci. USA 108, 2807–2812 (2011).
Chang, J. et al. Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. Nat. Med. 23, 450–460 (2017). This study shows that CKO of the CNS-specific receptor GPR124 in the endothelia of adult mice did not affect homeostatic BBB integrity, but resulted in BBB disruption and microvascular haemorrhage in mouse models of both ischemic stroke and glioblastoma, accompanied by reduced cerebrovascular canonical WNT–β-catenin signalling.
Cho, C., Smallwood, P. M. & Nathans, J. Reck and Gpr124 are essential receptor cofactors for Wnt7a/Wnt7b-specific signaling in mammalian CNS angiogenesis and blood-brain barrier regulation. Neuron 95, 1056–1073.e1055 (2017).
Cullen, M. et al. GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. Proc. Natl Acad. Sci. USA 108, 5759–5764 (2011).
Kuhnert, F. et al. Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124. Science 330, 985–989 (2010).
Zhou, Y. & Nathans, J. Gpr124 controls CNS angiogenesis and blood-brain barrier integrity by promoting ligand-specific canonical Wnt signaling. Dev. Cell 31, 248–256 (2014).
Chang, T. H., Hsieh, F. L., Smallwood, P. M., Gabelli, S. B. & Nathans, J. Structure of the RECK CC domain, an evolutionary anomaly. Proc. Natl Acad. Sci. USA 117, 15104–15111 (2020).
Boyé, K. et al. Endothelial Unc5B controls blood-brain barrier integrity. Nat. Commun. 13, 1169 (2022). This study shows that the endothelial receptor UNC5B controls BBB integrity by maintaining WNT–β-catenin signalling through CNS-specific netrin 1-enhanced UNC5B interaction with the WNT co-receptor LRP6, identifying netrin 1–UNC5B signalling as a ligand–receptor pathway that regulates BBB integrity, with implications for CNS diseases.
Huyghe, A. et al. Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling. Nat. Cell Biol. 22, 389–400 (2020).
Tam, S. J. et al. Death receptors DR6 and TROY regulate brain vascular development. Dev. Cell 22, 403–417 (2012).
Ye, X., Wang, Y. & Nathans, J. The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease. Trends Mol. Med. 16, 417–425 (2010).
Wang, Y. et al. Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. Cell 151, 1332–1344 (2012).
Wang, Z., Liu, C. H., Huang, S. & Chen, J. Wnt signaling in vascular eye diseases. Prog. Retin. Eye Res. 70, 110–133 (2019).
Barak, T. et al. PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans. Nat. Med. 27, 2165–2175 (2021).
Stenman, J. M. et al. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 322, 1247–1250 (2008).
Daneman, R. et al. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl Acad. Sci. USA 106, 641–646 (2009). This study identifies canonical WNT–β-catenin signalling as being specifically activated in CNS blood vessels, but not in non-CNS blood vessels, during development, and as being associated with the specific expression patterns of WNT7A and WNT7B in ventral regions and WNT1, WNT3, WNT3A and WNT4 in dorsal regions. This suggests an essential role for WNT–β-catenin signalling in driving CNS-specific angiogenesis.
Posokhova, E. et al. GPR124 functions as a WNT7-specific coactivator of canonical beta-catenin signaling. Cell Rep. 10, 123–130 (2015).
Cho, C., Wang, Y., Smallwood, P. M., Williams, J. & Nathans, J. Molecular determinants in Frizzled, Reck, and Wnt7a for ligand-specific signaling in neurovascular development. Elife https://doi.org/10.7554/eLife.47300 (2019).
Wang, Y. et al. Beta-catenin signaling regulates barrier-specific gene expression in circumventricular organ and ocular vasculatures. eLife 8, e43257 (2019).
Benz, F. et al. Low wnt/β-catenin signaling determines leaky vessels in the subfornical organ and affects water homeostasis in mice. eLife 8, e43818 (2019). This study shows that in mouse development, as well as in adult mice and zebrafish, circumventricular organ-derived ECs displayed low WNT pathway activity. Moreover, claudin 5 and PLVAP (also known as MECA-32 antigen) expression was heterogeneous, indicative of tight and leaky vessels, respectively, thereby contributing to our understanding of BBB maintenance at the molecular level.
Martowicz, A. et al. Endothelial beta-catenin signaling supports postnatal brain and retinal angiogenesis by promoting sprouting, tip cell formation, and VEGFR (vascular endothelial growth factor receptor) 2 expression. Arterioscler. Thromb. Vasc. Biol. https://doi.org/10.1161/atvbaha.119.312749 (2019).
Fujita, M. et al. Assembly and patterning of the vascular network of the vertebrate hindbrain. Development 138, 1705–1715 (2011).
Coelho-Santos, V., Berthiaume, A.-A., Ornelas, S., Stuhlmann, H. & Shih, A. Y. Imaging the construction of capillary networks in the neonatal mouse brain. Proc. Natl Acad. Sci. USA 118, e2100866118 (2021).
Wälchli, T. et al. Hierarchical imaging and computational analysis of three-dimensional vascular network architecture in the entire postnatal and adult mouse brain. Nat. Protoc. 16, 4564–4610 (2021). This study describes a step-by-step protocol that enables the characterization of brain vascular networks separately for capillaries and non-capillaries in the entire postnatal and adult mouse brain.
Miao, R. Q. et al. Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc. Natl Acad. Sci. USA 103, 10997–11002 (2006).
Zhao, B. et al. Nogo-B receptor is essential for angiogenesis in zebrafish via Akt pathway. Blood 116, 5423–5433 (2010).
Schwab, M. E. Functions of Nogo proteins and their receptors in the nervous system. Nat. Rev. Neurosci. 11, 799–811 (2010).
Rana, U. et al. Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice. Dev. Biol. 410, 190–201 (2016).
Park, E. J., Grabinska, K. A., Guan, Z. & Sessa, W. C. NgBR is essential for endothelial cell glycosylation and vascular development. EMBO Rep. 17, 167–177 (2016).
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K. & Carmeliet, P. Endothelial cell metabolism in health and disease. Trends Cell Biol. 28, 224–236 (2018).